<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002142.pub4" GROUP_ID="LUNGCA" ID="752599111915455440" MERGED_FROM="" MODIFIED="2016-10-11 13:46:26 +0100" MODIFIED_BY="Corynne Marchal" NOTES="&lt;p&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.2&lt;br&gt;Short title (no longer in use): Post-operative radiotherapy in NSCLC&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2016-10-11 13:16:38 +0100" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="LS2" REVMAN_SUB_VERSION="5.2.10 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="15.0">
<COVER_SHEET MODIFIED="2016-10-11 13:14:06 +0100" MODIFIED_BY="Sarah Burdett">
<TITLE>Postoperative radiotherapy for non-small cell lung cancer</TITLE>
<CONTACT>
<PERSON ID="13675" ROLE="AUTHOR">
<PREFIX>Miss</PREFIX>
<FIRST_NAME>Sarah</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Burdett</LAST_NAME>
<SUFFIX/>
<POSITION>Senior Research Scientist</POSITION>
<EMAIL_1>sarah.burdett@ucl.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Meta-analysis Group</DEPARTMENT>
<ORGANISATION>MRC Clinical Trials Unit at UCL</ORGANISATION>
<ADDRESS_1>Aviation House</ADDRESS_1>
<ADDRESS_2>125 Kingsway</ADDRESS_2>
<CITY>London</CITY>
<ZIP>WC2B 6NH</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 (0) 20 7670 4722</PHONE_1>
<PHONE_2/>
<FAX_1>+44 (0) 20 7670 4949</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2016-10-11 13:14:06 +0100" MODIFIED_BY="Sarah Burdett">
<PERSON ID="13675" ROLE="AUTHOR">
<PREFIX>Miss</PREFIX>
<FIRST_NAME>Sarah</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Burdett</LAST_NAME>
<SUFFIX/>
<POSITION>Senior Research Scientist</POSITION>
<EMAIL_1>sarah.burdett@ucl.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Meta-analysis Group</DEPARTMENT>
<ORGANISATION>MRC Clinical Trials Unit at UCL</ORGANISATION>
<ADDRESS_1>Aviation House</ADDRESS_1>
<ADDRESS_2>125 Kingsway</ADDRESS_2>
<CITY>London</CITY>
<ZIP>WC2B 6NH</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 (0) 20 7670 4722</PHONE_1>
<PHONE_2/>
<FAX_1>+44 (0) 20 7670 4949</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="16832" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Larysa</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Rydzewska</LAST_NAME>
<SUFFIX/>
<POSITION>Research Scientist</POSITION>
<EMAIL_1>larysa.rydzewska@ucl.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL>http://www.ctu.mrc.ac.uk/cochrane/ipdmg</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Meta-analysis Group</DEPARTMENT>
<ORGANISATION>MRC Clinical Trials Unit at UCL</ORGANISATION>
<ADDRESS_1>Aviation House</ADDRESS_1>
<ADDRESS_2>125 Kingsway</ADDRESS_2>
<CITY>London</CITY>
<ZIP>WC2B 6NH</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+ 44 (0) 207 670 4721</PHONE_1>
<PHONE_2/>
<FAX_1>+ 44 (0) 207 670 4949</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="8931" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Jayne</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Tierney</LAST_NAME>
<SUFFIX/>
<POSITION>Head</POSITION>
<EMAIL_1>jayne.tierney@ucl.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Meta-analysis Group</DEPARTMENT>
<ORGANISATION>MRC Clinical Trials Unit at UCL</ORGANISATION>
<ADDRESS_1>Aviation House</ADDRESS_1>
<ADDRESS_2>125 Kingsway</ADDRESS_2>
<CITY>London</CITY>
<ZIP>WC2B 6NH</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+ 44 20 7670 4724</PHONE_1>
<PHONE_2/>
<FAX_1>+ 44 20 7670 4865</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1607061136561982707944073174807" ROLE="AUTHOR">
<PREFIX>Mr</PREFIX>
<FIRST_NAME>David</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Fisher</LAST_NAME>
<SUFFIX/>
<POSITION>Statistician</POSITION>
<EMAIL_1>d.fisher@ucl.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>MRC Clinical Trials Unit at UCL</ORGANISATION>
<ADDRESS_1>125 Kingsway</ADDRESS_1>
<ADDRESS_2/>
<CITY>London</CITY>
<ZIP>WC2B 6NH</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="DA50035982E26AA2001A7553C87D8867" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Mahesh</FIRST_NAME>
<MIDDLE_INITIALS>KB</MIDDLE_INITIALS>
<LAST_NAME>Parmar</LAST_NAME>
<SUFFIX/>
<POSITION>Head</POSITION>
<EMAIL_1>m.parmar@ucl.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>MRC Clinical Trials Unit at UCL</ORGANISATION>
<ADDRESS_1>222 Euston Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>London</CITY>
<ZIP>NW1 2DA</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 20 7670 4729</PHONE_1>
<PHONE_2/>
<FAX_1>+44 20 7670 4818</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1411201517316221764415392838241" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Rodrigo</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Arriagada</LAST_NAME>
<SUFFIX/>
<POSITION>Professor</POSITION>
<EMAIL_1>rodrigo.arriagada@gustaveroussy.fr</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>33643200294</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Karolinska Institutet</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Stockholm</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="SE">Sweden</COUNTRY>
<PHONE_1>33142114931</PHONE_1>
<PHONE_2/>
<FAX_1>33142115299</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="D425812D82E26AA20112CE69F012F222" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Jean Pierre</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Pignon</LAST_NAME>
<SUFFIX>MD, PhD</SUFFIX>
<POSITION/>
<EMAIL_1>jean-pierre.pignon@gustaveroussy.fr</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Plateforme LNCC de Méta-analyse en Oncologie et Service de Biostatistique et d&#8217;Epidémiologie</DEPARTMENT>
<ORGANISATION>Gustave Roussy Cancer Campus</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Villejuif</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="FR">France</COUNTRY>
<PHONE_1>+ 33 1 4211 4565</PHONE_1>
<PHONE_2/>
<FAX_1>+ 33 1 4211 5258</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1411191537194308539344994794814" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Cecile</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Le Pechoux</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>cecile.lepechoux@gustaveroussy.fr</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Département de Radiothérapie</DEPARTMENT>
<ORGANISATION>Gustave Roussy Cancer Campus</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Villejuif</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="FR">France</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<GROUP ID="z1607011612234542511916568975297">
<GROUP_NAME>on behalf of the PORT Meta-analysis Trialists Group</GROUP_NAME>
<CONTACT_PERSON>Sarah Burdett</CONTACT_PERSON>
<EMAIL_1>sarah.burdett@ucl.ac.uk</EMAIL_1>
<URL/>
<ADDRESS>
<DEPARTMENT>Meta-analysis Group</DEPARTMENT>
<ORGANISATION>MRC Clinical Trials Unit at UCL</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>London</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</GROUP>
</CREATORS>
<DATES MODIFIED="2016-09-29 09:46:50 +0100" MODIFIED_BY="Sarah Burdett">
<UP_TO_DATE>
<DATE DAY="8" MONTH="7" YEAR="2016"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="8" MONTH="7" YEAR="2016"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2000"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2000"/>
<LAST_CITATION_ISSUE ISSUE="10" YEAR="2016"/>
</DATES>
<WHATS_NEW MODIFIED="2016-09-29 13:02:03 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2016-09-29 09:47:46 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="18" MONTH="7" YEAR="2016"/>
<DESCRIPTION>
<P>Changes in authorship</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-09-29 13:02:03 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="18" MONTH="7" YEAR="2016"/>
<DESCRIPTION>
<P>Full update, no new studies - conclusions not changed, some changes to subgroup conclusions as newer, more appropriate methods have been used. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2016-09-09 10:26:35 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2016-04-26 14:09:33 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="5" MONTH="11" YEAR="2009"/>
<DESCRIPTION>
<P>New PLS added</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2016-09-09 10:26:35 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="12" MONTH="5" YEAR="2009"/>
<DESCRIPTION>
<P>Name of group author slightly changed</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2009-05-12 13:24:12 +0100" MODIFIED_BY="José Angel Exposito">
<DATE DAY="19" MONTH="1" YEAR="2009"/>
<DESCRIPTION>
<P>Full update, new trial data included</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-02-13 08:51:05 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="22" MONTH="5" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2016-09-09 10:26:35 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="25" MONTH="10" YEAR="2004"/>
<DESCRIPTION>
<P>Substantive amendments made</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Medical Research Council</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>NHS R&amp;D programme project grant NCP/U03</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2016-10-11 13:16:38 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2016-09-07 12:14:28 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2009-02-13 08:50:23 +0000" MODIFIED_BY="[Empty name]">Postoperative radiotherapy for non-small cell lung cancer</TITLE>
<SUMMARY_BODY MODIFIED="2016-09-07 12:14:28 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Review question</B>
</P>
<P>Do patients with non-small cell lung cancer live longer if they are given radiotherapy after surgery?</P>
<P>
<B>Background</B>
</P>
<P>Non-small cell lung cancer is the most common type of lung cancer. If the tumour is early stage, is not too big and has not spread to other parts of the body, doctors usually operate to remove it. Radiotherapy (treatment with x-rays) is sometimes given after the operation, aiming to kill any remaining cancer cells.</P>
<P>In 1998, we did a systematic review and meta-analysis of individual participant data looking at trials of this treatment - postoperative radiotherapy (PORT). This review brought together information from all patients who took part in similar trials. These trials compared what happened to people with non-small cell lung cancer who were given radiotherapy after surgery and those who had surgery without radiotherapy. Results were first published in <I>The Lancet</I> in 1998.<BR/>
<BR/>Since this review was completed, many trials have been done. To ensure that available evidence is as up-to-date as possible, we carried out a new systematic review and meta-analysis of individual participant data that included all trials, old and new. As for the 1998 review, this review aimed to find out if giving radiotherapy after surgery (1) helps patients live longer, (2) stops cancer from coming back (recurrence) and (3) stops cancer from spreading to other parts of the body (metastases).</P>
<P>These updated results were first published in <I>Lung Cancer</I> in 2013.</P>
<P>
<B>Study characteristics</B>
</P>
<P>We searched for relevant trials up to 8 July 2016. These studies brought together available trial data from all over the world, with 11 trials and 2343 patients. Trials were carried out between 1966 and 1998.</P>
<P>
<B>Key results</B>
</P>
<P>Results showed that fewer people given PORT treatment lived for two years after the operation (53 out of every 100 patients) than those not given PORT after the operation (58 out of every 100 patients). Researchers reported no difference in effects of PORT by types of patients included in trials.</P>
<P>Researchers did not routinely collect quality of life information during the trials, and it was unlikely that any benefit of PORT would offset the observed survival disadvantage.</P>
<P>Radiotherapy given after successful removal of tumour at operation is not beneficial for patients with non-small cell lung cancer and should not be used as routine treatment; however, further research into new types of radiotherapy for patients at higher risk of recurrence is ongoing.</P>
<P>
<B>Quality of evidence</B>
</P>
<P>These systematic reviews and meta-analyses use individual participant data, which are considered the gold standard for this type of review. We included all eligible trials, if possible, no matter what language they were published in, or whether or not they were published. This meta-analysis included 88% of all participants in eligible trials.</P>
<P>Studies were well designed and conducted and addressed the review question, with consistent effects noted across trials. The impact of any data not included in our analyses is small.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2016-09-27 14:31:12 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2016-09-07 10:14:27 +0100" MODIFIED_BY="[Empty name]">
<P>The role of postoperative radiotherapy (PORT) in the treatment of patients with completely resected non-small cell lung cancer (NSCLC) was not clear. A systematic review and individual participant data meta-analysis was undertaken to evaluate available evidence from randomised controlled trials (RCTs). These results were first published in <I>Lung Cancer</I> in 2013.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2016-09-07 10:14:19 +0100" MODIFIED_BY="[Empty name]">
<P>To evaluate the effects of PORT on survival and recurrence in patients with completely resected NSCLC. To investigate whether predefined patient subgroups benefit more or less from PORT.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2016-09-09 10:27:11 +0100" MODIFIED_BY="[Empty name]">
<P>We supplemented MEDLINE and CANCERLIT searches (1965 to 8 July 2016) with information from trial registers, handsearching of relevant meeting proceedings and discussion with trialists and organisations.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2016-09-07 10:13:26 +0100" MODIFIED_BY="[Empty name]">
<P>We included trials of surgery versus surgery plus radiotherapy, provided they randomised participants with NSCLC using a method that precluded prior knowledge of treatment assignment.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2016-09-07 10:15:39 +0100" MODIFIED_BY="[Empty name]">
<P>We carried out a quantitative meta-analysis using updated information from individual participants from all randomised trials. We sought data on all participants from those responsible for the trial. We obtained updated individual participant data (IPD) on survival and date of last follow-up, as well as details on treatment allocation, date of randomisation, age, sex, histological cell type, stage, nodal status and performance status. To avoid potential bias, we requested information on all randomised participants, including those excluded from investigators' original analyses. We conducted all analyses on intention-to-treat on the endpoint of survival.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2016-09-27 14:31:12 +0100" MODIFIED_BY="[Empty name]">
<P>We identified 14 trials evaluating surgery versus surgery plus radiotherapy. Individual participant data were available for 11 of these trials, and our analyses are based on 2343 participants (1511 deaths). Results show a significant adverse effect of PORT on survival, with a hazard ratio of 1.18, or an 18% relative increase in risk of death. This is equivalent to an absolute detriment of 5% at two years (95% confidence interval (CI) 2% to 9%), reducing overall survival from 58% to 53%. Subgroup analyses showed no differences in effects of PORT by any participant subgroup covariate.</P>
<P>We did not undertake analysis of the effects of PORT on quality of life and adverse events. Investigators did not routinely collect quality of life information during these trials, and it was unlikely that any benefit of PORT would offset the observed survival disadvantage. We considered risk of bias in the included trials to be low.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2016-09-07 10:16:50 +0100" MODIFIED_BY="[Empty name]">
<P>Results from 11 trials and 2343 participants show that PORT is detrimental to those with completely resected non-small cell lung cancer and should not be used in the routine treatment of such patients. Results of ongoing RCTs will clarify the effects of modern radiotherapy in patients with N2 tumours.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2016-09-27 14:32:15 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2016-09-27 14:31:20 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2016-09-07 10:19:57 +0100" MODIFIED_BY="[Empty name]">
<P>Worldwide, carcinoma of the lung is the main cause of cancer death. More than 1.5 million new cases are diagnosed each year (<LINK REF="REF-Jemal-2011" TYPE="REFERENCE">Jemal 2011</LINK>), about 85% of which involve non-small cell lung cancer (<LINK REF="REF-American-Cancer-Society-2007" TYPE="REFERENCE">American Cancer Society 2007</LINK>). Surgery is the treatment of choice for early non-small cell lung cancer (NSCLC) (<LINK REF="REF-NSCLCCG-1995" TYPE="REFERENCE">NSCLCCG 1995</LINK>), but only about 20% of tumours are suitable for potentially curative surgery (<LINK REF="REF-Datta-2003" TYPE="REFERENCE">Datta 2003</LINK>). Even for patients with apparently completely resected disease, survival is only around 40% at five years. In an effort to improve local-regional control of the disease and to increase survival, investigators have explored adjuvant postoperative radiotherapy (PORT) as a therapeutic option.</P>
</CONDITION>
<INTERVENTION MODIFIED="2016-09-07 10:20:21 +0100" MODIFIED_BY="[Empty name]">
<P>This review concentrated on randomised controlled trials (RCTs) that tested surgery alone compared with surgery followed by radiotherapy. Radiotherapy in these trials was given by cobalt therapy, by cobalt therapy and linear accelerators or by linear accelerators only.</P>
</INTERVENTION>
<THEORY MODIFIED="2016-09-07 10:20:29 +0100" MODIFIED_BY="[Empty name]">
<P>Radiotherapy may be given after surgery with the aim of killing any remaining cancer cells.</P>
</THEORY>
<IMPORTANCE MODIFIED="2016-09-27 14:31:20 +0100" MODIFIED_BY="[Empty name]">
<P>Despite the conduct of several RCTs (most in the 1980s and 1990s) that recruited a total of more than 2000 patients, the role of PORT in the treatment of patients with NSCLC has remained unclear. Individually, trials showed inconclusive and conflicting results. However, because of their size (74 to 539 participants), individual trials did not have sufficient statistical power to detect the moderate survival differences that might be expected with PORT. We therefore initiated an individual participant data meta-analysis to assess this question. This approach to meta-analysis and systematic review involves the central collection, validation and analysis of original trial data. It does not rely on data extracted from publications. At the outset, the project management group contacted the investigators responsible for each trial and established the PORT Meta-analysis Trialists Group, under whose auspices the meta-analysis was conducted and published. This review was first published in <I>The</I> <I>Lancet</I> in 1998 (<LINK REF="REF-PORT-1998" TYPE="REFERENCE">PORT 1998</LINK>). In 2005, the meta-analysis was updated (<LINK REF="REF-PORT-2005" TYPE="REFERENCE">PORT 2005</LINK>) with data from one new trial (<LINK REF="STD-Italy-2002" TYPE="STUDY">Italy 2002</LINK>). In 2009, the meta-analysis was updated again to include data from another new trial (<LINK REF="STD-Korea-2007" TYPE="STUDY">Korea 2007</LINK>). However, since this review was last updated, new methods developed to assess treatment by patient covariates that are methodologically more appropriate and less prone to bias have prompted this latest update of the Cochrane review (<LINK REF="REF-Fisher-2011" TYPE="REFERENCE">Fisher 2011</LINK>). Furthermore, changes over time to the tumour-node-metastasis (TNM) staging system have been taken into account in this update, and although the data did not permit use of the seventh TNM edition, they did allow us to convert tumour stage from the fourth (<LINK REF="REF-Mountain-1987" TYPE="REFERENCE">Mountain 1987</LINK>) to the fifth/sixth (<LINK REF="REF-Mountain-1997" TYPE="REFERENCE">Mountain 1997</LINK>) edition.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2016-09-07 10:27:26 +0100" MODIFIED_BY="[Empty name]">
<P>To evaluate effects of PORT on survival and recurrence in patients with completely resected NSCLC. To investigate whether predefined patient subgroups benefit more or less from PORT.</P>
</OBJECTIVES>
<METHODS MODIFIED="2016-09-27 14:31:31 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2016-09-07 14:27:12 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2016-09-07 10:28:10 +0100" MODIFIED_BY="[Empty name]">
<P>To be included, both published and unpublished completed trials had to be properly randomised using established methods (not quasi-randomised). Trials could not have been confounded by additional therapeutic differences between the two arms and must have commenced randomisation on or after 1 January 1965. Trials should have aimed to randomise participants with completely resected non-small cell lung cancer between radiotherapy and no immediate further treatment. Trials should not have used orthovoltage radiotherapy.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2016-09-07 14:26:47 +0100" MODIFIED_BY="[Empty name]">
<P>Eligible trials included individuals with histologically confirmed NSCLC who had undergone a potentially curative resection. We included in the meta-analyses individual participant data from all randomised participants and, when possible, obtained data for individuals who had been excluded from the original trial analyses. We excluded from the meta-analyses, participants with small cell lung cancer, who were included in early trials that randomised all types of lung cancer.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2016-09-07 10:28:44 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Surgery versus surgery + postoperative radiotherapy (PORT).</LI>
</UL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2016-09-07 14:27:12 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Survival.</LI>
<LI>Recurrence-free survival.</LI>
<LI>Local recurrence-free survival.</LI>
<LI>Distant recurrence-free survival.</LI>
</UL>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2016-09-07 10:28:58 +0100" MODIFIED_BY="[Empty name]">
<P>The primary outcome of overall survival was defined as the time from randomisation until death by any cause. Living participants were censored on the date of last follow-up.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2016-09-07 14:27:12 +0100" MODIFIED_BY="[Empty name]">
<P>Recurrence-free survival was defined as the time from randomisation until first recurrence, or death by any cause. Participants alive without disease were censored on the date of last follow-up. To avoid bias from under-reporting of subsequent events, time to local-regional recurrence was defined as the time from randomisation until first local-regional recurrence, with participants experiencing earlier distant recurrences censored at the time of distant recurrence. Similarly, for time to distant recurrence, participants experiencing earlier local-regional recurrences were censored on that date. Participants who died without recurrence were censored on the date of death. Data on quality of life were not routinely collected in these trials; therefore we could not analyse the data in this review.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2016-09-27 14:28:06 +0100" MODIFIED_BY="[Empty name]">
<P>To limit publication bias, we included published and unpublished trials with no restrictions based on language. We carried out searches of MEDLINE (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>) and CANCERLIT from 1965 (using The Cochrane Collaboration's optimal strategy (<LINK REF="REF-Lefebvre-2001" TYPE="REFERENCE">Lefebvre 2001</LINK>; <LINK REF="REF-Lefebvre-2008" TYPE="REFERENCE">Lefebvre 2008</LINK>). We supplemented searches of trial registers by conducting handsearches of conference proceedings and reference lists of trial publications and review articles. We asked our collaborators if they knew of additional trials. We carried out the most recent searches in July 2016.</P>
<P>In 1997, we identified trials by electronic searches of MEDLINE and CANCERLIT, using a modified version of the optimal search strategy of The Cochrane Collaboration (<LINK REF="REF-Dickersin-1995" TYPE="REFERENCE">Dickersin 1995</LINK>), supplemented by handsearches of Proceedings of the American Society of Clinical Oncology (ASCO) (1990 to 2016) and the World Conference on Lung Cancer (1990 to 2015) and bibliographies of books, reviews and specialist journals. We also searched trial registers (Cochrane Central Register of Controlled Trials (CENTRAL), the National Cancer Institute Physicians Data Query Clinical Protocols and United Kingdom Co-ordinating Committee for Cancer Research)and asked all trialists who took part in the meta-analysis to help to identify additional trials. We regularly updated searches to identify new trials and to assess the status of any ongoing trials. Search updates in October 2002 and August 2003 identified one new eligible trial (<LINK REF="STD-Italy-2002" TYPE="STUDY">Italy 2002</LINK>), and the search update carried out in 2009 identified two new eligible trials: a Polish trial (<LINK REF="STD-Dymek-2003" TYPE="STUDY">Dymek 2003</LINK>) and a Korean trial published as an abstract (<LINK REF="STD-Korea-2007" TYPE="STUDY">Korea 2007</LINK>). We last carried out searches in July 2016 and identified no new eligible trials.</P>
<ELECTRONIC_SEARCHES MODIFIED="2016-09-07 12:14:15 +0100" MODIFIED_BY="[Empty name]">
<P>We modified The Cochrane Collaboration's optimum search strategy for retrieving RCTs from MEDLINE (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>) to specifically retrieve RCTs of radiotherapy for NSCLC, and we used this search strategy to search MEDLINE and CANCERLIT (1965 to 2016).</P>
<P>In addition, we searched the following electronic bibliographic databases.</P>
<UL>
<LI>The Cochrane Central Register of Controlled Trials (CENTRAL) (1995 to 8 July 2016) (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>).</LI>
<LI>Proceedings of annual meetings of the American Society for Clinical Oncology (ASCO) (1995 to 2016).</LI>
</UL>
<P>We used the following trial registers to supplement searches of electronic databases with trials that were not (yet) published or were still recruiting patients.</P>
<UL>
<LI>United Kingdom Coordinating Committee on Cancer Research (UKCCCR) Trials Register.</LI>
<LI>ClinicalTrials.gov.</LI>
<LI>Physicians Data Query Protocols (open and closed).</LI>
<LI>Current Controlled Trials &#8216;metaRegister&#8217; of controlled trials.</LI>
</UL>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2016-09-07 10:37:11 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Handsearches</HEADING>
<P>We carried out the following handsearches to identify trials that may have been reported only as abstracts, or that might have been missed in the searches described above.</P>
<UL>
<LI>Proceedings of the American Society for Clinical Oncology (ASCO), 1990 to 1994.</LI>
<LI>Proceedings of the International Association for the Study of Lung Cancer (IASLC) World Lung Cancer Conference 1990 to 2015.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Searches of reference lists</HEADING>
<P>We searched the bibliographies of all identified trials and review articles.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Correspondence</HEADING>
<P>We asked all participating trialists to review and supplement a provisional list of trials.</P>
</SUBSECTION>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2016-09-27 14:31:31 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2016-09-07 10:42:38 +0100" MODIFIED_BY="[Empty name]">
<P>Two members of the Project Management Group (SB, LR) checked all titles and abstracts identified by electronic searching and handsearching of conference proceedings, and obtained full publications for those thought to be potentially relevant. We sought individual participant data (IPD) from trial authors, including updated follow-up, when available.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2016-09-07 14:28:14 +0100" MODIFIED_BY="[Empty name]">
<P>We sought IPD for all eligible trials, as well as updated information on survival, recurrence and date of last follow-up, and details of treatment allocated, date of randomisation, age, sex, histological cell type, stage and performance status.</P>
<P>We used standard checks to identify missing data. We verified data, for example, by checking the order of the dates of randomisation, and assessed data validity and consistency. To assess randomisation integrity, we checked patterns of treatment allocation and balance of baseline characteristics by treatment arm. We checked follow-up of surviving participants to ensure that it was balanced by treatment arm and up-to-date. We resolved queries, and each trial investigator or statistician verified the final database.</P>
<P>As stage was recorded using different classification systems, for the purposes of this meta-analysis we translated all stage data to a common staging system, which has been updated since the original analysis to reflect the TNM sixth edition classification (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>; <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>).</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2016-09-07 14:29:00 +0100" MODIFIED_BY="[Empty name]">
<P>We assessed included studies using the risk of bias tool of The Cochrane Collaboration, as outlined in Table 8.5c of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>), two authors (SB, LR) checked these studies. We considered adequate sequence generation and allocation concealment to be most important; therefore a judgement of low risk was desirable for these domains for all trials. Blinding was not appropriate owing to the nature of the treatments, and any issues surrounding reporting of incomplete outcome data, selective outcome reporting or attrition bias were overcome by collection of IPD.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2016-09-07 10:45:46 +0100" MODIFIED_BY="[Empty name]">
<P>Unless otherwise stated, we prespecified all analyses in the protocols and carried out an intention-to-treat analysis. For each outcome, we used the log-rank expected number of events and variance to calculate individual trial hazard ratios (HRs), which we pooled across trials using the fixed-effect model (<LINK REF="REF-Yusuf-1985" TYPE="REFERENCE">Yusuf 1985</LINK>). We presented overall survival using simple (non-stratified) Kaplan-Meier curves (<LINK REF="REF-Kaplan-1958" TYPE="REFERENCE">Kaplan 1958</LINK>) and computed median follow-up for all participants by using the reverse Kaplan-Meier method (<LINK REF="REF-Schemper-1996" TYPE="REFERENCE">Schemper 1996</LINK>).</P>
<P>We analysed 'raw' IPD using in-house software (SCHARP), then entered the log-rank summary statistics of these analyses (O-E and variance) into RevMan (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>). We presented results as absolute differences at five years, calculated with the HR and baseline event rate on the surgery alone arm; we assumed proportional hazards (<LINK REF="REF-Parmar-1995" TYPE="REFERENCE">Parmar 1995</LINK>). We similarly calculated confidence intervals for absolute differences from the baseline event rate and the HR at 95% confidence interval boundary values.</P>
<P>To explore any impact of trial characteristics on effects of adjuvant chemotherapy on overall survival, we calculated pooled HRs for each prespecified trial group and used Chi<SUP>2</SUP> tests for interaction to investigate differences in treatment effect across trial groups.</P>
</EFFECT_MEASURES>
<MISSING_DATA MODIFIED="2016-09-07 10:45:56 +0100" MODIFIED_BY="[Empty name]">
<P>We outlined all desired variables in a protocol (available on request) and requested missing variables from those who carried out the trials.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2016-09-07 10:46:01 +0100" MODIFIED_BY="[Empty name]">
<P>We used Chi<SUP>2</SUP> tests and the I<SUP>2</SUP> statistic (<LINK REF="REF-Higgins-2002" TYPE="REFERENCE">Higgins 2002</LINK>) to test for differences in treatment effect across groups of trials or groups of participants.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2016-09-07 10:46:11 +0100" MODIFIED_BY="[Empty name]">
<P>As we collected IPD, we encountered no reporting biases.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2016-09-07 10:46:24 +0100" MODIFIED_BY="[Empty name]">
<P>When we could get data, we included all eligible trials in the analyses. We carried out these analyses in SCHARP (in-house software), Stata (<LINK REF="REF-Stata-2013" TYPE="REFERENCE">Stata 2013</LINK>) and RevMan (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>).</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2016-09-27 14:31:31 +0100" MODIFIED_BY="[Empty name]">
<P>To investigate differences in treatment effect across participant subgroups, we undertook Cox regressions, including the relevant treatment by subgroup interaction term within each trial. We pooled these interaction coefficients (HRs) across trials (<LINK REF="REF-Fisher-2011" TYPE="REFERENCE">Fisher 2011</LINK>) and investigated whether differences in treatment effect could be identified that varied with participant age, sex, histological cell type, tumour stage or performance status.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2016-09-07 10:47:32 +0100" MODIFIED_BY="[Empty name]">
<P>We outlined in the protocol that HRs for overall survival would be calculated, excluding any trials that were clear outliers.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2016-09-27 14:32:15 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2016-09-07 10:53:40 +0100" MODIFIED_BY="[Empty name]">
<P>We identified 14 eligible trials (one unpublished) and included 11 trials in the review (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>). We could not include three trials: Data for two trials were unavailable (<LINK REF="STD-Dymek-2003" TYPE="STUDY">Dymek 2003</LINK> (150 participants); <LINK REF="STD-LCSG-841" TYPE="STUDY">LCSG 841</LINK> (five participants)), and it was unclear whether one study of 155 participants, which was reported as a randomised controlled trial (RCT), was indeed randomised. We were unable to obtain appropriate data for this trial (<LINK REF="STD-Austria-1996" TYPE="STUDY">Austria 1996</LINK>) (see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>).</P>
<P>Therefore, this update is based on the results of 11 RCTs (<LINK REF="STD-Belgium-1966" TYPE="STUDY">Belgium 1966</LINK>; <LINK REF="STD-CAMS-1981" TYPE="STUDY">CAMS 1981</LINK>; <LINK REF="STD-EORTC-08861" TYPE="STUDY">EORTC 08861</LINK>; <LINK REF="STD-GETCB-04CB86" TYPE="STUDY">GETCB 04CB86</LINK>; <LINK REF="STD-GETCB-05CB88" TYPE="STUDY">GETCB 05CB88</LINK>; <LINK REF="STD-Italy-2002" TYPE="STUDY">Italy 2002</LINK>; <LINK REF="STD-Korea-2007" TYPE="STUDY">Korea 2007</LINK>; <LINK REF="STD-LCSG-773" TYPE="STUDY">LCSG 773</LINK>; <LINK REF="STD-Lille-1985" TYPE="STUDY">Lille 1985</LINK>; <LINK REF="STD-MRC-LU11" TYPE="STUDY">MRC LU11</LINK>; <LINK REF="STD-Slovenia-1988" TYPE="STUDY">Slovenia 1988</LINK>) and 2343 individuals. Across these trials, PORT doses ranged from 30 Gy to 60 Gy, given in between 10 and 30 fractions, and considerable diversity was evident in other aspects of radiotherapy planning. All trials included participants with completely resected tumours for which the disease stage was no greater than IIIA. Most trials provided updated follow-up giving a median of 4.4 years for surviving participants (2.3 to 11.4 years for individual trials). Baseline participant characteristics show that most participants were male with stage II/III squamous cell carcinoma (although histology was unknown for a relatively large number of participants) with good performance status (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>).</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2016-09-07 10:54:48 +0100" MODIFIED_BY="[Empty name]">
<P>We included only trials with adequate methods of randomisation. We excluded trials that used quasi-random methods, such as birth date. We thoroughly checked all raw data received on individual participants to ensure both the accuracy of the meta-analysis database and the quality of randomisation and follow-up. We resolved all queries and verified final database entries through discussion with the responsible trial investigator or statistician. No RCTs were blinded owing to the nature of the intervention, but the primary outcome is not likely to be influenced by lack of blinding. For two trials, allocation concealment was unclear - one trial was unpublished (<LINK REF="STD-EORTC-08861" TYPE="STUDY">EORTC 08861</LINK>), and one was published only as an abstract (<LINK REF="STD-Korea-2007" TYPE="STUDY">Korea 2007</LINK>) - but checks on IPD and correspondence with those who supplied the data reassured us that the data had been adequate. We received IPD for all outcomes of interest; therefore we considered reporting bias to be low for all RCTs. We considered all included trials to be at low risk of bias (see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> and <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2016-09-27 14:32:15 +0100" MODIFIED_BY="[Empty name]">
<P>Results were based on information from 11 RCTs (2343 participants), representing 88% of individuals from all eligible randomised trials. We collected data for 140 out of 142 participants who had been excluded from the original published trial analyses and were reinstated in this meta-analysis. For one trial, which randomised all histological types of lung cancer (<LINK REF="STD-Belgium-1966" TYPE="STUDY">Belgium 1966</LINK>), we excluded the 20 participants with small cell tumours from the meta-analysis. Survival and recurrence data were available for all trials. All trials provided information on age, sex and stage, and nine trials provided data on histology (<LINK REF="STD-Belgium-1966" TYPE="STUDY">Belgium 1966</LINK>; <LINK REF="STD-CAMS-1981" TYPE="STUDY">CAMS 1981</LINK>; <LINK REF="STD-EORTC-08861" TYPE="STUDY">EORTC 08861</LINK>; <LINK REF="STD-Italy-2002" TYPE="STUDY">Italy 2002</LINK>; <LINK REF="STD-Korea-2007" TYPE="STUDY">Korea 2007</LINK>; <LINK REF="STD-LCSG-773" TYPE="STUDY">LCSG 773</LINK>; <LINK REF="STD-Lille-1985" TYPE="STUDY">Lille 1985</LINK>; <LINK REF="STD-MRC-LU11" TYPE="STUDY">MRC LU11</LINK>; <LINK REF="STD-Slovenia-1988" TYPE="STUDY">Slovenia 1988</LINK>). Performance status data were available for only four trials (<LINK REF="STD-EORTC-08861" TYPE="STUDY">EORTC 08861</LINK>; <LINK REF="STD-Italy-2002" TYPE="STUDY">Italy 2002</LINK>; <LINK REF="STD-MRC-LU11" TYPE="STUDY">MRC LU11</LINK>; <LINK REF="STD-Slovenia-1988" TYPE="STUDY">Slovenia 1988</LINK>) and were insufficient for assessment of treatment by covariate interactions. All but two trials provided cause of death data (coded as NSCLC, treatment-related or other) (<LINK REF="STD-Italy-2002" TYPE="STUDY">Italy 2002</LINK>; <LINK REF="STD-LCSG-773" TYPE="STUDY">LCSG 773</LINK>), although the trialists themselves questioned the reliability of this information for many trials.</P>
<SUBSECTION>
<HEADING LEVEL="3">Survival</HEADING>
<P>Survival data were available for all trials and included information from 2343 participants and 1511 deaths (777 PORT, 734 surgery alone). Although the confidence intervals (CIs) for individual trial results were wide, combined results showed a significant adverse effect of PORT on survival (P = 0.001), with a hazard ratio (HR) of 1.18 (95% CI 1.07 to 1.31) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>), or an 18% relative increase in risk of death. This was equivalent to an absolute detriment of 5% at two years (95% CI 2% to 9%), reducing overall survival from 58% to 53%. Survival curves (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>) appeared to diverge at around four months and remained apart for the five years to which they could be drawn with reasonable reliability. There was some evidence of increased statistical heterogeneity between trials in the current update (I<SUP>2 </SUP>= 40%, P = 0.08), compared with the original 1998 meta-analysis. However, the random-effects result is similar (HR 1.17, 95% CI 1.02 to 1.34, P = 0.02), and heterogeneity appears largely driven by the Italian trial (<LINK REF="STD-Italy-2002" TYPE="STUDY">Italy 2002</LINK>). A sensitivity analysis excluding this trial reduces heterogeneity (I<SUP>2 </SUP>= 31%, P = 0.16) and gives similar fixed-effect (HR 1.20, 95% CI 1.08 to 1.33, P = 0.0005) and random-effects results (HR 1.20, 95% CI 1.06 to 1.37, P = 0.005).</P>
<P>Cause of death information coded as NSCLC, treatment related or other was available for nine trials. Of 595 coded deaths on PORT, 82% were attributed to NSCLC, 4% to treatment-related causes and 14% to other causes. For the 565 coded deaths on surgery alone, these figures are 89%, 2% and 9%, respectively.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Local recurrence-free survival</HEADING>
<P>Data on local-regional recurrence were available from all trials. Analysis of local-regional recurrence-free survival, based on 1556 events (498 local-regional recurrences (200 on PORT, 298 on surgery alone) and 1058 deaths (593 on PORT, 465 on surgery alone)), gave a HR of 1.12 (95% CI 1.01 to 1.24), significantly in favour of surgery alone (P = 0.03) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). There was evidence of statistical heterogeneity between trials (I<SUP>2</SUP> = 47%, P = 0.04), which was not apparent in the 1998 analysis (I<SUP>2</SUP> = 29%, P = 0.19), and for this outcome, the random-effects result is less convincing (HR 1.10, 95% CI 0.95 to 1.27, P = 0.19) than the fixed-effect result. However, exclusion of the Italian trial (<LINK REF="STD-Italy-2002" TYPE="STUDY">Italy 2002</LINK>) again reduces heterogeneity to non-significant levels (I<SUP>2</SUP> = 22%, P = 0.23), as well as giving similar fixed-effect (HR 1.15, 95% CI 1.04 to 1.27, P = 0.008) and random-effects estimates (HR 1.15, 95% CI 1.02 to 1.29, P = 0.02). Results may suggest an increase in local-regional recurrence on the PORT arm, but the number of local-regional recurrences alone shows less local-regional recurrence on the PORT arm and more events when deaths without local-regional recurrence are included.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Distant recurrence-free survival</HEADING>
<P>All trials provided data on distant recurrence. Analysis of distant recurrence-free survival based on 1570 events (892 distant recurrences (438 on PORT, 454 on surgery alone) and 678 deaths (361 on PORT, 317 on surgery alone)) gave an HR of 1.13 (95% CI 1.02 to 1.24) in favour of surgery alone (P = 0.02) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). There was no evidence of gross statistical heterogeneity between trials (I<SUP>2 </SUP>= 31%, P = 0.15).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Overall recurrence-free survival</HEADING>
<P>A total of 1597 events were observed, 810 on PORT and 787 on surgery alone. Of these, 445 first events were deaths, 260 participants had local-regional recurrences and 654 had distant recurrences (238 participants had both local-regional and distant recurrences, of which 110 were recorded on the same date). The overall HR of 1.10 (95% CI 0.99 to 1.21) potentially suggests an adverse effect of PORT (P = 0.07) (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). This 10% relative increase in risk of recurrence or death was equivalent to an absolute detriment of 3% at two years (95% CI 0% to 7%), reducing the recurrence-free survival rate from 48% to 45%. As with local-regional recurrence-free survival, there was some evidence of increased statistical heterogeneity between trials (I<SUP>2 </SUP>= 44%, P = 0.06) that was not present in the 1998 analysis (I<SUP>2 </SUP>= 26%, P = 0.21), and a random-effects analysis produces a less convincing result (HR 1.09, 95% CI 0.95 to 1.25, P = 0.23). However, a sensitivity analysis excluding the Italian trial (<LINK REF="STD-Italy-2002" TYPE="STUDY">Italy 2002</LINK>) not only reduces heterogeneity (I<SUP>2 </SUP>= 20%, P = 0.26) but also gives similar fixed-effect (HR 1.13, 95% CI 1.02 to 1.24, P = 0.02) and random-effects (HR 1.13, 95% CI 1.00 to 1.26, P = 0.04) results.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Analyses by trial characteristics</HEADING>
<P>We planned analysis for overall survival by trial characteristic based on the planned energy beam delivery method (cobalt only, cobalt and linac, linac only) and radiotherapy dose (&lt; 45 Gy, &#8805; 45 Gy). We found no difference in effects of treatment on overall survival depending on delivery method (P = 0.18) (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>). We did find a difference by dose of radiotherapy (P = 0.02) (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>), but 80% of data is in the &gt;=45 Gy group, and the result in the &lt; 45 Gy group subgroup alone is not significant.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Analyses by participant covariates</HEADING>
<P>Based on data from all trials, for survival there was no evidence to suggest that PORT was differentially effective by age (interaction P = 0.67), sex (P = 0.49) or histology (P = 0.38). For analysis by stage, we could not include three trials because all participants were in a single stage category (<LINK REF="STD-Italy-2002" TYPE="STUDY">Italy 2002</LINK>, <LINK REF="STD-Lille-1985" TYPE="STUDY">Lille 1985</LINK> stage I only; <LINK REF="STD-Slovenia-1988" TYPE="STUDY">Slovenia 1988</LINK> stage III only). Data from the remaining eight trials provide no evidence to suggest that PORT was differentially effective by stage within individual trials (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>), but the meta-analysis of these interactions suggests that PORT may be most detrimental in earlier-stage patients, although the result was not significant (HR = 0.87, 95% CI 0.72 to 1.04, P = 0.12) (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>). Similar results were observed whether or not trials included all three stages or only stage II and III participants (<LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>; <LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>). Exploratory analyses of how the effect of PORT on local-regional, distant and overall recurrence-free survival varies by stage gave similar results. For analysis by nodal status, we could not include four trials because all participants were in a single subgroup category with N0 (<LINK REF="STD-Belgium-1966" TYPE="STUDY">Belgium 1966</LINK>; <LINK REF="STD-Italy-2002" TYPE="STUDY">Italy 2002</LINK>; <LINK REF="STD-Lille-1985" TYPE="STUDY">Lille 1985</LINK>) or N2/3 (<LINK REF="STD-Slovenia-1988" TYPE="STUDY">Slovenia 1988</LINK>) disease. Data from the remaining seven trials provided no evidence to suggest that PORT was differentially effective by nodal status within individual trials (<LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK>), nor in a meta-analysis of these interactions (HR = 0.92, 95% CI 0.76 to 1.11, P = 0.39) (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P>
<P>Results for stage and nodal status are different from previously published results (<LINK REF="REF-PORT-1998" TYPE="REFERENCE">PORT 1998</LINK>; <LINK REF="REF-PORT-2005" TYPE="REFERENCE">PORT 2005</LINK>) largely for two reasons. Here, we have used a method (<LINK REF="REF-Fisher-2011" TYPE="REFERENCE">Fisher 2011</LINK>) to examine whether the effect of PORT varied by participant covariates that was different from the method used in the original review in 1998 (<LINK REF="REF-PORT-1998" TYPE="REFERENCE">PORT 1998</LINK>), and in the previous updates in 2005 and 2009 (<LINK REF="REF-PORT-2005" TYPE="REFERENCE">PORT 2005</LINK>). This new method is more appropriate and is less prone to bias. We could not calculate several covariate interactions for trials contributing participants in only a single covariate category; therefore we did not include these studies; this approach, although correct, can provide less power than the methods used previously. Trials not included here also happen to have quite extreme results and have had undue influence on previous analyses.</P>
<P>In this update, we wanted to take account of changes to the TNM staging system; although the data do not allow us to use the seventh edition, they do allow us to convert stage from the fourth to the sixth edition; the major impact of this is that patients previously classified as T3N0M0 (stage IIIA) have been reclassified as stage IIB. This change affected 98 participants and <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK> shows results for stage and nodal status according to the combination of changes made.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2016-09-27 14:30:13 +0100" MODIFIED_BY="[Empty name]">
<P>At the outset of this project, despite enrolment of more than 2000 participants in randomised trials, it remained unclear whether postoperative radiotherapy (PORT) was effective for the treatment of patients with non-small cell lung cancer (NSCLC). The original 1998 meta-analysis found a significant adverse effect of PORT on survival (P = 0.001) with a hazard ratio (HR) of 1.21 (95% confidence interval (CI) 1.08 to 1.34), or a 21% relative increase in risk of death. We undertook this systematic review and individual participant data meta-analysis to produce a comprehensive, reliable and up-to-date summary of the average effect of PORT in patients with NSCLC, to provide reliable guidance for clinical practice and future research. Therefore, when a new trial of 111 participants was published (<LINK REF="STD-Korea-2007" TYPE="STUDY">Korea 2007</LINK>), we included this study in an update of the analyses.</P>
<P>Overall, for the primary endpoint of survival, there was clear evidence of a detrimental effect of PORT for patients with completely resected NSCLC. The 18% relative increase in risk of death associated with PORT, equivalent to an overall reduction in survival from 58% to 53% at five years, represents a considerable hazard for these patients. In contrast to the original meta-analysis and previous updates, this update, using new and more appropriate methods, did not provide evidence that the relative effect of PORT was smaller or larger for patients of any category defined by age, sex or histology. For analysis by stage, PORT tended to be most detrimental in patients with earlier-stage disease, but this result was not significant once 98 patients had been reclassified according to the updated TNM system. Likewise, analysis by nodal status shows a much less convincing relationship between the effect of PORT and nodal status. Also, in the case of both stage and nodal status analyses, trials with participants in only a single stage or nodal status category (<LINK REF="STD-Lille-1985" TYPE="STUDY">Lille 1985</LINK>; <LINK REF="STD-Italy-2002" TYPE="STUDY">Italy 2002</LINK>; <LINK REF="STD-Slovenia-1988" TYPE="STUDY">Slovenia 1988</LINK>) had a major impact on the original analyses, and so their appropriate exclusion from these analyses is significant. However, this means that despite inclusion of more trials overall, less data were included in this compared with the original analyses so power is more limited.</P>
<P>All analyses of local-regional (P = 0.02), distant (P = 0.02) and overall (P = 0.08) recurrence-free survival (i.e. time to recurrence or death) have suggested an overall adverse effect of PORT. However, the observed detriment was less for these endpoints than for overall survival. For local-regional recurrence-free survival, results were driven largely by survival (as deaths account for the majority of events). This suggests that antitumour activity may be attributable to radiotherapy, and that increased risk of death from PORT may be attributable to other mechanisms. Analysis of the local-regional recurrence-free interval (i.e. the time to local-regional recurrence with death and distant recurrence censored) was not presented because such analysis would be difficult to interpret and would be potentially seriously flawed. This difficulty arose because increased risk of death with PORT may mean that patients treated with PORT die before their tumour has had time to recur locally. Thus, such measurement was likely to be an overestimation of local-regional control.</P>
<P>Inclusion of the most recent trial (<LINK REF="STD-Korea-2007" TYPE="STUDY">Korea 2007</LINK>) has brought the total number of participants to 2343 across 11 randomised controlled trials (RCTs). As would be expected, the addition of this modestly sized trial has not substantially changed the overall effect of PORT on survival. As evidence from new trials has accumulated, there has been some increase in heterogeneity, particularly in relation to the Italian trial (<LINK REF="STD-Italy-2002" TYPE="STUDY">Italy 2002</LINK>), which, it should be noted, included only participants with stage I disease.</P>
<P>However, a significant detriment of PORT for survival persists, with similar estimates, irrespective of whether a fixed-effect or a random-effects model is used. Results for local-regional and overall recurrence-free survival are less convincing. Furthermore, although trials have been conducted over a period of 40 years, with changes in diagnosis and assessment of recurrence and radiotherapy, no clear evidence indicates that the effect of PORT has improved over the decades.</P>
<P>In particular, much discussion over the past few years has focused on modern radiotherapy techniques such as those used in some of the trials included here; the suggestion is that modern radiotherapy (delivered by linear accelerator) may be less detrimental than older methods (delivered by cobalt machines). Recent literature-based meta-analyses (<LINK REF="REF-Billiet-2014" TYPE="REFERENCE">Billiet 2014</LINK>) could not confirm this, providing a reported risk ratio (RR) for overall survival of 0.85 (95% confidence interval (CI) 0.59 to 1.22, P = 0.38) for trials that used only linear accelerators. Indeed when we ran this same analysis using our individual participant data, for those trials that used only linear accelerators (albeit on a different selection of trials), we observed a hazard ratio (HR) for overall survival of 1.02 (95% CI 0.80 to 1.31, P = 0.85; <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>). Another recent literature-based meta-analysis (<LINK REF="REF-Patel-2014" TYPE="REFERENCE">Patel 2014</LINK>) has suggested benefit of PORT for overall survival when radiotherapy has been given only with linear accelerators (HR = 0.77, 95% CI 0.62 to 0.92, P = 0.02); however, this review used a combination of three RCTs (some of which included chemotherapy) and eight retrospective studies. Results of an ongoing trial may clarify this matter (<LINK REF="STD-Lung-ART_x002d_IGR-2006_x002f_1202" TYPE="STUDY">Lung ART-IGR 2006/1202</LINK>).</P>
<P>Although this meta-analysis did not directly address quality of life (none of the trials collected data on patient-reported quality of life measures), it was unlikely that any benefits of PORT would offset the observed survival disadvantage. Indeed the additional time spent undergoing treatment and the side effects of radiation could reasonably be expected to impair at least short-term quality of life.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2016-09-07 14:32:23 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2016-09-07 12:12:15 +0100" MODIFIED_BY="[Empty name]">
<P>Although the radiotherapy used in most of the included trials is now considered suboptimal, this update still provides the best evidence that postoperative radiotherapy (PORT) has an adverse effect on survival. There is now less compelling evidence that the effect of PORT varies by stage, and in particular nodal status, but PORT should not be used routinely unless supporting evidence can be obtained from an ongoing trial of modern PORT techniques (<LINK REF="STD-Lung-ART_x002d_IGR-2006_x002f_1202" TYPE="STUDY">Lung ART-IGR 2006/1202</LINK>).</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2016-09-07 14:32:23 +0100" MODIFIED_BY="[Empty name]">
<P>This meta-analysis has shown a clear adverse effect of postoperative radiotherapy on survival. However, whilst PORT still tends to be detrimental in early-stage disease, the result is no longer significant. Researchers must evaluate PORT using modern radiotherapy techniques. One recent systematic review (<LINK REF="REF-Patel-2014" TYPE="REFERENCE">Patel 2014</LINK>) has suggested a benefit of PORT when radiotherapy is given only with the use of linear accelerators; this review used a combination of randomised controlled trials (RCTs) (some of which included chemotherapy) and retrospective studies. Another recent review (<LINK REF="REF-Billiet-2014" TYPE="REFERENCE">Billiet 2014</LINK>) could not confirm benefit. A trial including participants with N2 disease is currently ongoing (NCT00410683). If further trials are initiated, accurate and detailed information on the cause of death will be important, as will data regarding surgical resection and radiotherapy technique. Collection of such data may help to clarify whether a combination of radiation with surgery or radiation alone is the cause of excess deaths with postoperative radiotherapy.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2016-10-11 13:16:38 +0100" MODIFIED_BY="[Empty name]">
<P>The following investigators, groups and project management team* form the original PORT Meta-analysis Group and participated in this meta-analysis.</P>
<P>R Arriagada, Institut Gustave-Roussy, Villejuif, France; AH Brichet, JJ Lafitte, Hôpital Calmette, CHRU, Lille, France; S Burdett*, D Fisher, DJ Girling, MKB Parmar*, LHM Rydzewska*, RJ Stephens, LA Stewart*, JF Tierney, MRC Clinical Trials Unit at UCL, UK; B Dautzenberg, Groupe d'Etude et de Traitement des Cancers Bronchiques (GETCB); M Debevec, V Kovac, Institute of Oncology, Zaloska 2 , Ljublijana, Slovenia; A Gregor, European Organization for Research and Treatment of Cancer, Brussels, Belgium; JH Park, Korea Cancer Center, Seoul, Korea; S Piantadosi, Lung Cancer Study Group, USA; JP Pignon, Institut Gustave-Roussy, Villejuif, France; P Rocmans, Dept of Thoracic Surgery, Hôpitaux St Pierre et Erasme, Brussels, Belgium; R Souhami*, University College London, Medical School, UK; V Torri, Istituto di Ricerche Farmacologiche "Mario Negri", Milan, Italy; P Van Houtte, Dept of Radiotherapy, Institut Jules Bordet, Brussels, Belgium; L Trodella, Department of Radiation Oncology, Università Cattolica del S. Cuore, Rome; M Wang, Dept of Radiation Oncology and Surgery, Chinese Academy of Medical Sciences, Beijing, China.</P>
<P>The authors thank the European Organization for Research and Treatment of Cancer for permission to the the data from EORTC 08861 for this research. The contents of this publication and methods used are solely the responsibility of the authors and do not necessarily represent the official views of the EORTC.</P>
<P>Co-ordination of the meta-analysis and the collaborators' meeting was funded by the UK National Health Service Research and Development Cancer Programme (project grant NCP/U03). We would like to thank all those patients who took part in the trials and contributed to this research. The meta-analysis would not have been possible without their help or without the collaborating institutions, which kindly supplied their trial data.</P>
<P>We are particularly grateful to Desmond Curran, Stanley Dische and Michele Saunders for helpful comments on the 1998 manuscript.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known. </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2016-09-07 11:22:43 +0100" MODIFIED_BY="[Empty name]">
<P>The writing group for the current version of this review consisted of S Burdett, LHM Rydzewska, JF Tierney, MKB Parmar, D Fisher, R Arriagada, JP Pignon and C Le Pechoux, on behalf of the PORT Meta-analysis Trialists Group.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2016-10-11 13:46:26 +0100" MODIFIED_BY="Corynne Marchal">
<STUDIES MODIFIED="2016-09-09 10:26:35 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2016-09-07 12:08:37 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="MIX" ID="STD-Belgium-1966" MODIFIED="2009-02-13 09:18:11 +0000" MODIFIED_BY="[Empty name]" NAME="Belgium 1966" YEAR="1966">
<REFERENCE MODIFIED="2009-02-13 08:51:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>van Houtte P, Rocmans P, Smets P, Goffin JC, Lustman-Marecal J, Vanderhoeft P, et al</AU>
<TI>Postoperative radiation therapy in lung cancer: a controlled trial after resection of curative design</TI>
<SO>International Journal of Radiation, Oncology, Biology and Physics</SO>
<YR>1980</YR>
<VL>6</VL>
<PG>983-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2715563"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-02-13 09:18:11 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2715562"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-CAMS-1981" MODIFIED="2009-02-13 08:51:05 +0000" MODIFIED_BY="[Empty name]" NAME="CAMS 1981" YEAR="1981">
<REFERENCE MODIFIED="2009-02-13 08:51:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Feng QF, Wang M, Wang LJ, Yang ZY, Zhang YG, Zhang DW, et al</AU>
<TI>A study of postoperative radiotherapy in patients with non-small cell lung cancer: a randomized trial</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2000</YR>
<VL>47</VL>
<NO>4</NO>
<PG>925-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2715565"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2715564"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-EORTC-08861" MODIFIED="2016-09-07 12:08:37 +0100" MODIFIED_BY="[Empty name]" NAME="EORTC 08861" YEAR="1986">
<REFERENCE MODIFIED="2016-09-07 12:08:37 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;van Zandwijk N, Gregor A, Rocmans P. EORTC 08861 - Phase III randomised trial of adjuvant radiotherapy vs no adjuvant therapy with completely resected non-small cell lung cancer. Unpublished.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2016-09-07 12:08:37 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>EORTC 08861(unpublished)</AU>
<TI>Phase III randomised trial of adjuvant radiotherapy vs no adjuvant therapy with completely resected non-small cell lung cancer</TI>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2715567"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-02-13 09:12:01 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2715566"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-GETCB-04CB86" MODIFIED="2016-09-07 11:37:37 +0100" MODIFIED_BY="[Empty name]" NAME="GETCB 04CB86" YEAR="1986">
<REFERENCE MODIFIED="2016-09-07 11:37:37 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Dautzenberg B, Arriagada R, Chammard AB, Jarema A, Mezzetti M, Mattson K, Lagrange JL, Le Pechoux C, Lebeau B, Chastang C, et al. A randomised trial evaluating post-op RT in NSCLC after complete surgical resection. Cancer (In press).&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2016-09-07 11:37:37 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>Dautzenberg B, Arriagada R, Chammard AB, Jarema A, Mezzetti M, Mattson K et al, for the Groupe d'Etude et de Traitement des Cancers Bronchiques</AU>
<TI>A controlled study of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma</TI>
<SO>Cancer</SO>
<YR>1999</YR>
<VL>86</VL>
<NO>2</NO>
<PG>265-273</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2715569"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2715568"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-GETCB-05CB88" MODIFIED="2016-09-07 11:38:28 +0100" MODIFIED_BY="[Empty name]" NAME="GETCB 05CB88" YEAR="1988">
<REFERENCE MODIFIED="2016-09-07 11:38:28 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Dautzenberg B, Arriagada R, Chammard AB, Jarema A, Mezzetti M, Mattson K, Lagrange JL, Le Pechoux C, Lebeau B, Chastang C, et al. A randomised trial evaluating post-op RT in NSCLC after complete surgical resection. Cancer (In press).&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2016-09-07 11:38:28 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>Dautzenberg B, Arriagada R, Chammard AB, Jarema A, Mezzetti M, Mattson K et al, for the Groupe d'Etude et de Traitement des Cancer Bronchiques</AU>
<TI>A controlled study of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma</TI>
<SO>Cancer</SO>
<YR>1999;86(2):265-73</YR>
<VL>86</VL>
<NO>2</NO>
<PG>265-273</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2715571"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2715570"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Italy-2002" NAME="Italy 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Trodella L, Granone P, Valente S, Valentini V, Balducci M, Mantini G, et al</AU>
<TI>Adjuvant radiotherapy in non-small cell lung cancer with pathological stage I: definitive results of a phase III randomised trial</TI>
<SO>Radiotherapy and Oncology</SO>
<YR>2002</YR>
<VL>62</VL>
<PG>11-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2715573"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2715572"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Korea-2007" MODIFIED="2009-02-06 14:32:25 +0000" MODIFIED_BY="Jenny Bellorini" NAME="Korea 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-02-06 14:32:25 +0000" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Park JH</AU>
<TI>Postoperative adjuvant therapy for stage IIIa non-small cell lung cancer</TI>
<SO>Journal of Thoracic Oncology</SO>
<YR>2007</YR>
<VL>2 (8 Suppl 4)</VL>
<PG>S651</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2715575"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2715574"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-LCSG-773" NAME="LCSG 773" YEAR="1978">
<REFERENCE NOTES="&lt;p&gt;Lung Cancer Study Group. Effects of postoperative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lung. N Engl J Med 1986; 315 (22): 1377-81&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lung Cancer Study Group</AU>
<TI>Effects of postoperative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lung</TI>
<SO>New England Journal of Medicine</SO>
<YR>1986</YR>
<VL>315</VL>
<NO>22</NO>
<PG>1377-81</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2715577"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2715576"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Lille-1985" MODIFIED="2009-02-13 08:51:05 +0000" MODIFIED_BY="[Empty name]" NAME="Lille 1985" YEAR="1985">
<REFERENCE MODIFIED="2009-02-13 08:51:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lafitte JJ, Ribet ME, Prévost BM, Gosselin BH, Copin M-C, Brichet AH</AU>
<TI>Post-irradiation for T2 N0 M0 non-small cell carcinoma: a prospective randomized study</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>1996</YR>
<VL>62</VL>
<PG>830-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2715579"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2715578"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-MRC-LU11" NAME="MRC LU11" YEAR="1986">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Stephens RJ, Girling DJ, Bleehen NM, Moghissi K, Yosef HMA, Machin D</AU>
<TI>The role of post-operative radiotherapy in non-small cell lung cancer: a multicentre randomised trial in patients with pathologically staged T1-2, N1-2, M0 disease</TI>
<SO>British Journal of Cancer</SO>
<YR>1996</YR>
<VL>74</VL>
<PG>632-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2715581"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2715580"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Slovenia-1988" MODIFIED="2009-02-13 08:51:05 +0000" MODIFIED_BY="[Empty name]" NAME="Slovenia 1988" YEAR="1988">
<REFERENCE MODIFIED="2009-02-13 08:51:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Debevec M, Bitenc M, Vidmar S, Rott T, Orel J, Strojan P, et al</AU>
<TI>Post-operative radiotherapy for radically resected N2 non-small cell lung cancer: randomised clinical study 1988-92</TI>
<SO>Lung Cancer</SO>
<YR>1996</YR>
<VL>14</VL>
<PG>99-107</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2715583"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2715582"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2016-09-07 12:03:36 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Austria-1996" MODIFIED="2009-02-06 14:33:46 +0000" MODIFIED_BY="Jenny Bellorini" NAME="Austria 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-02-06 14:33:46 +0000" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mayer R, Smolle-Juettner F-M, Szolar D, Stuecklschweiger GF, Quehenberger F, Friehs G, et al</AU>
<TI>Postoperative radiotherapy in radically resected non-small cell lung cancer</TI>
<SO>Chest</SO>
<YR>1997</YR>
<VL>112</VL>
<PG>954-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2715585"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2715584"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dymek-2003" MODIFIED="2016-09-07 11:42:02 +0100" MODIFIED_BY="[Empty name]" NAME="Dymek 2003" YEAR="2003">
<REFERENCE MODIFIED="2016-09-07 11:42:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dymek P, Kowalska T, Reinfuss M, Walasek T, Zareba-Szlubowska M, Mitus J et al</AU>
<TI>The efficacy of adjuvant thoracic radiation therapy in NSCLC patients with ipsilateral mediastinal/hilar lymph node involvement</TI>
<TO>Ocena skutecznosci pooperacyjnej teleradioterapii chorych na NDRP zoperowanych miejscowo doszczetnie z obecnoscia przerzutow w usunietych wezlach chlonnych srodpiersia albo wneki (kontrolowane doswiadczenie kliniczne)</TO>
<SO>Pneumonol Alergol Pol</SO>
<YR>2003</YR>
<VL>71</VL>
<NO>11-12</NO>
<PG>496-503</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2715587"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2715586"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-LCSG-841" MODIFIED="2016-09-07 12:03:36 +0100" MODIFIED_BY="[Empty name]" NAME="LCSG 841" YEAR="">
<REFERENCE MODIFIED="2016-09-07 12:03:36 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Lung Cancer Study Group. Phase III randomised study of post-op radiotherapy vs no radiotherapy following resection of non-small cell lung cancer. Unpublished.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2016-09-07 12:03:36 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Lung Cancer Study Group (Unpublished)</AU>
<TI>Phase III randomised study of post-op radiotherapy vs no radiotherapy following resection of non-small cell lung cancer</TI>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2715589"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2715588"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2009-01-19 18:44:53 +0000" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2016-09-09 10:26:35 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="UNPUB" ID="STD-Lung-ART_x002d_IGR-2006_x002f_1202" MODIFIED="2016-09-09 10:26:35 +0100" MODIFIED_BY="[Empty name]" NAME="Lung ART-IGR 2006/1202" YEAR="">
<REFERENCE MODIFIED="2016-09-09 10:26:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>LUNG ART-IGR 2006/1202 (ongoing)</AU>
<TI>Phase III study comparing post-operative conformal radiotherapy to no post-operative radiotherapy in patients with completely resected non-small cell lung cancer and mediastinal N2 involvement</TI>
<SO>NCT00410683</SO>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4380120"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4380119"/></IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2016-09-09 10:26:35 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2016-09-09 10:26:35 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-American-Cancer-Society-2007" MODIFIED="2016-09-09 10:26:35 +0100" MODIFIED_BY="[Empty name]" NAME="American Cancer Society 2007" TYPE="JOURNAL_ARTICLE">
<AU>American Cancer Society</AU>
<TI>Cancer Facts and Figures 2007</TI>
<SO>Atlanta: American Cancer Society,</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Billiet-2014" MODIFIED="2016-09-07 11:42:59 +0100" MODIFIED_BY="[Empty name]" NAME="Billiet 2014" TYPE="JOURNAL_ARTICLE">
<AU>Billiet C, Dealuwe H, Peeters S, Vansteenkiste J, Dooms C, Haustermans K et al</AU>
<TI>Corrigendum to "Modern post-operative radiotherapy for stage III non-small cell lung cancer may improve local control and survival: A meta-analysis"</TI>
<SO>Radiotherapy and Oncology</SO>
<YR>2014</YR>
<VL>113</VL>
<NO>2</NO>
<PG>300-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Datta-2003" MODIFIED="2016-09-07 11:44:14 +0100" MODIFIED_BY="[Empty name]" NAME="Datta 2003" TYPE="JOURNAL_ARTICLE">
<AU>Datta D, Lahiri B</AU>
<TI>Preoperative evaluation of patients undergoing lung resection surgery</TI>
<SO>Chest</SO>
<YR>2003</YR>
<VL>123</VL>
<PG>2096-103</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dickersin-1995" NAME="Dickersin 1995" TYPE="BOOK_SECTION">
<AU>Dickersin K, Scherer R, Lefebvre C</AU>
<TI>Identifying relevant studies for systematic reviews</TI>
<SO>Systematic Reviews</SO>
<YR>1995</YR>
<PG>17-36</PG>
<ED>Chalmers I, Altman DG</ED>
<PB>BMJ Publishing Group</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fisher-2011" MODIFIED="2016-09-07 11:45:03 +0100" MODIFIED_BY="[Empty name]" NAME="Fisher 2011" TYPE="JOURNAL_ARTICLE">
<AU>Fisher DJ, Copas AJ, Tierney JF, Parmar MKB</AU>
<TI>A critical review of methods for the assessment of patient-level interactions in individual patient data (IPD) meta-analysis of randomised trials, and guidance for practitioners</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<PG>949-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2002" NAME="Higgins 2002" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG</AU>
<TI>Quantifying heterogeneity in a meta-analysis</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>1539-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2016-09-09 10:26:35 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="BOOK">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions - Version 5.0.1 [updated in September 2011]</SO>
<YR>2011. www.cochrane-handbook.org</YR>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jemal-2011" MODIFIED="2016-09-07 11:59:37 +0100" MODIFIED_BY="[Empty name]" NAME="Jemal 2011" TYPE="JOURNAL_ARTICLE">
<AU>Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D</AU>
<TI>Global cancer statistics</TI>
<SO>CA: A Cancer Journal for Clinicians</SO>
<YR>2011</YR>
<VL>61</VL>
<PG>69-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kaplan-1958" NAME="Kaplan 1958" TYPE="JOURNAL_ARTICLE">
<AU>Kaplan EL, Meier P</AU>
<TI>Nonparametric estimation from incomplete observation</TI>
<SO>Journal of the American Statistical Association</SO>
<YR>1958</YR>
<VL>53</VL>
<PG>457-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-2001" MODIFIED="2016-09-07 11:48:44 +0100" MODIFIED_BY="[Empty name]" NAME="Lefebvre 2001" TYPE="BOOK_SECTION">
<AU>Lefebvre C, Clarke MJ</AU>
<TI>Identifying randomised trials</TI>
<SO>Systematic Reviews in Healthcare</SO>
<YR>2001</YR>
<PG>69-87</PG>
<EN>2nd</EN>
<ED>Egger M, Smith GD, Altman DG</ED>
<PB>BMJ Publishing Group</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-2008" MODIFIED="2016-09-07 11:50:08 +0100" MODIFIED_BY="[Empty name]" NAME="Lefebvre 2008" TYPE="BOOK_SECTION">
<AU>Lefebvre C, Manheimer E, Glanville J, on behalf of the Cochrane Information Retrieval Methods Group</AU>
<TI>Searching for studies</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions</SO>
<YR>2008</YR>
<PG>95-150</PG>
<ED>Higgins JPT, Green S</ED>
<PB>John Wiley &amp; Sons Ltd</PB>
<CY>Chichester</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mountain-1987" MODIFIED="2016-09-07 11:51:40 +0100" MODIFIED_BY="[Empty name]" NAME="Mountain 1987" TYPE="JOURNAL_ARTICLE">
<AU>Mountain CF</AU>
<TI>The new international staging system for lung cancer</TI>
<SO>Surgical Clinics of North America</SO>
<YR>1987</YR>
<VL>67</VL>
<NO>5</NO>
<PG>925-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mountain-1997" MODIFIED="2016-09-07 11:51:52 +0100" MODIFIED_BY="[Empty name]" NAME="Mountain 1997" TYPE="JOURNAL_ARTICLE">
<AU>Mountain CF</AU>
<TI>Revisions in the International System for Staging Lung Cancer</TI>
<SO>Chest</SO>
<YR>1997</YR>
<VL>111</VL>
<NO>6</NO>
<PG>1710-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NSCLCCG-1995" MODIFIED="2016-09-07 11:52:07 +0100" MODIFIED_BY="[Empty name]" NAME="NSCLCCG 1995" TYPE="JOURNAL_ARTICLE">
<AU>Non-small Cell Lung Cancer Collaborative Group</AU>
<TI>Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials</TI>
<SO>British Medical Journal</SO>
<YR>1995</YR>
<VL>311</VL>
<NO>7010</NO>
<PG>899-909</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Parmar-1995" MODIFIED="2016-09-07 11:53:05 +0100" MODIFIED_BY="[Empty name]" NAME="Parmar 1995" TYPE="BOOK">
<AU>Parmar MKB, Machin D</AU>
<SO>Survival Analysis: A Practical Approach</SO>
<YR>1995</YR>
<PB>John Wiley &amp; Sons Ltd</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Patel-2014" MODIFIED="2016-09-07 11:53:41 +0100" MODIFIED_BY="[Empty name]" NAME="Patel 2014" TYPE="JOURNAL_ARTICLE">
<AU>Patel SH, Ma Y, Wernicke AG, Nori D, Chao KSC, Parashar B</AU>
<TI>Evidence supporting contemporary post-operative radiation therapy (PORT) using linear accelerators in N2 lung cancer</TI>
<SO>Lung Cancer</SO>
<YR>2014</YR>
<VL>84</VL>
<PG>156-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2016-09-09 10:26:35 +0100" MODIFIED_BY="[Empty name]" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2014</YR>
<EN>5.3.5. Copenhagen: The Nordic Cochrane Centre</EN>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schemper-1996" MODIFIED="2016-09-09 10:26:35 +0100" MODIFIED_BY="[Empty name]" NAME="Schemper 1996" TYPE="JOURNAL_ARTICLE">
<AU>Schemper M, Smith TL</AU>
<TI>A note on quantifying follow-up in studies of failure time</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<NO>4</NO>
<PG>343-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stata-2013" MODIFIED="2015-01-15 12:50:35 +0000" MODIFIED_BY="[Empty name]" NAME="Stata 2013" TYPE="COMPUTER_PROGRAM">
<TI>StataCorp 2013. Stata Statistical Software: Release 13</TI>
<YR>2013</YR>
<PB>StataCorp LP</PB>
<CY>College Station, TX</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yusuf-1985" MODIFIED="2009-02-13 08:51:05 +0000" MODIFIED_BY="[Empty name]" NAME="Yusuf 1985" TYPE="JOURNAL_ARTICLE">
<AU>Yusuf S, Peto R, Lewis J, Collins R, Sleight P</AU>
<TI>Beta-blockade during and after myocardial infarction: an overview of the randomised trials</TI>
<SO>Progress in Cardiovascular Diseases</SO>
<YR>1985</YR>
<VL>27</VL>
<NO>5</NO>
<PG>335-71</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2016-09-09 10:26:35 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-PORT-1998" NAME="PORT 1998" TYPE="JOURNAL_ARTICLE">
<AU>PORT Meta-analysis Trialists Group</AU>
<TI>Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<PG>257-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-PORT-2005" MODIFIED="2016-09-09 10:26:35 +0100" MODIFIED_BY="[Empty name]" NAME="PORT 2005" TYPE="JOURNAL_ARTICLE">
<AU>Burdett S, Stewart L, on behalf of the PORT Meta-analysis Trialist Group</AU>
<TI>Postoperative radiotherapy in non-small cell lung cancer: update of an individual patient data meta-analysis</TI>
<SO>Lung Cancer</SO>
<YR>2005</YR>
<VL>47</VL>
<NO>1</NO>
<PG>81-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-PORT-2013" MODIFIED="2016-09-09 10:26:35 +0100" MODIFIED_BY="[Empty name]" NAME="PORT 2013" TYPE="JOURNAL_ARTICLE">
<AU>Burdett S, Rydzewska L, Tierney JF, Fisher DJ</AU>
<TI>A closer look at the effects of postoperative radiotherapy by stage and nodal status: updated results of an individual participant data meta-analysis in non-small-cell lung cancer</TI>
<SO>Lung Cancer</SO>
<YR>2013</YR>
<VL>80</VL>
<PG>350-2</PG>
<IDENTIFIERS MODIFIED="2013-06-14 14:35:19 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2016-09-07 11:34:33 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2016-09-07 11:34:33 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2016-09-07 11:22:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Belgium-1966">
<CHAR_METHODS MODIFIED="2009-02-13 08:50:24 +0000" MODIFIED_BY="[Empty name]">
<P>1966 to 1977</P>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-09-07 11:22:44 +0100" MODIFIED_BY="[Empty name]">
<P>224 patients<BR/>Stages I, II, III</P>
<P>Trial data used in subgroup analyses for sex, age and histology</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-09-07 11:22:49 +0100" MODIFIED_BY="[Empty name]">
<P>Surgery + radiotherapy vs surgery alone<BR/>RT details<BR/>60 Gy in 30 fractions in 6 weeks<BR/>Prescription technique: isodose 90%<BR/>Machine used: Co60<BR/>Average field size (cm): 15 × 9<BR/>Clinical target volume: bronchial stump, hilum, mediastinum<BR/>Technique: spinal cord blocks, oblique fields, lateral fields</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-02-13 08:50:24 +0000" MODIFIED_BY="[Empty name]">
<P>Survival</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-09-07 11:22:56 +0100" MODIFIED_BY="[Empty name]">
<P>20 small cell participants excluded from meta-analysis<BR/>Unable to supply data for 2 participants</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-09-07 11:23:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-CAMS-1981">
<CHAR_METHODS MODIFIED="2009-02-13 08:50:24 +0000" MODIFIED_BY="[Empty name]">
<P>1981 to 1995</P>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-09-07 11:23:38 +0100" MODIFIED_BY="[Empty name]">
<P>317 patients<BR/>Stages II, III</P>
<P>Trial data used in subgroup analyses for sex, age, histology, stage and nodal status</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-09-07 11:23:50 +0100" MODIFIED_BY="[Empty name]">
<P>Surgery + radiotherapy vs surgery alone<BR/>RT details<BR/>60 Gy in 30 fractions in 6 weeks<BR/>Prescription technique: at midplane<BR/>Machine used: Co60 and linac<BR/>Average field size (cm): 6 × 12<BR/>Clinical target volume: hilum, mediastinum<BR/>Technique: spinal cord blocks, oblique fields, lateral fields</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-02-13 08:50:24 +0000" MODIFIED_BY="[Empty name]">
<P>Survival</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-02-13 08:50:24 +0000" MODIFIED_BY="[Empty name]">
<P>Abstract only</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-09-07 11:34:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-EORTC-08861">
<CHAR_METHODS MODIFIED="2009-02-13 08:50:24 +0000" MODIFIED_BY="[Empty name]">
<P>1986 to 1990 RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-09-07 11:34:33 +0100" MODIFIED_BY="[Empty name]">
<P>106 patients<BR/>Stages II, III</P>
<P>Trial data used in subgroup analyses for sex, age, histology, stage and nodal status</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-09-07 11:24:25 +0100" MODIFIED_BY="[Empty name]">
<P>Surgery + radiotherapy vs surgery alone<BR/>RT details<BR/>56 Gy in 28 fractions in 5.5 weeks<BR/>Prescription technique: central axis, at the midplane<BR/>Machine used: linac<BR/>Average field size (cm): 15 × 10<BR/>Clinical target volume: hilum, mediastinum<BR/>Technique: composite plans</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-02-13 08:50:24 +0000" MODIFIED_BY="[Empty name]">
<P>Survival</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-02-13 08:50:24 +0000" MODIFIED_BY="[Empty name]">
<P>Unpublished trial</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-09-07 11:34:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-GETCB-04CB86">
<CHAR_METHODS MODIFIED="2016-09-07 11:34:33 +0100" MODIFIED_BY="[Empty name]">
<P>1986 to 1994</P>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-09-07 11:25:15 +0100" MODIFIED_BY="[Empty name]">
<P>189 patients<BR/>Stages I, II, III</P>
<P>Trial data used in subgroup analyses for sex, age, stage and nodal status</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-09-07 11:25:18 +0100" MODIFIED_BY="[Empty name]">
<P>Surgery + radiotherapy vs surgery alone<BR/>RT details<BR/>60 Gy in 24 to 30 fractions in 6 weeks<BR/>Prescription technique: isocentre<BR/>Machine used: Co60 and linac (majority linac)<BR/>Average field size (cm): unavailable<BR/>Clinical target volume: bronchial stump, hilum, mediastinum<BR/>Technique: spinal cord blocks, oblique fields, lateral fields</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-02-13 08:50:24 +0000" MODIFIED_BY="[Empty name]">
<P>Survival</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-02-06 14:00:16 +0000" MODIFIED_BY="Jenny Bellorini">
<P>Same publication as <LINK REF="STD-GETCB-05CB88" TYPE="STUDY">GETCB 05CB88</LINK>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-09-07 11:34:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-GETCB-05CB88">
<CHAR_METHODS MODIFIED="2009-02-13 08:50:24 +0000" MODIFIED_BY="[Empty name]">
<P>1988 to 1994</P>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-09-07 11:34:33 +0100" MODIFIED_BY="[Empty name]">
<P>539 patients<BR/>Stages I, II, III</P>
<P>Trial data used in subgroup analyses for sex, age, stage and nodal status</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-09-07 11:26:00 +0100" MODIFIED_BY="[Empty name]">
<P>Surgery + radiotherapy vs surgery alone<BR/>RT details<BR/>60 Gy in 24 to 30 fractions in 6 weeks<BR/>Prescription technique: isocentre<BR/>Machine used: Co60 and linac (majority linac)<BR/>Average field size (cm): unavailable<BR/>Clinical target volume: bronchial stump, hilum, mediastinum<BR/>Technique: spinal cord blocks, oblique fields, lateral fields</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-02-13 08:50:24 +0000" MODIFIED_BY="[Empty name]">
<P>Survival</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-02-06 14:01:50 +0000" MODIFIED_BY="Jenny Bellorini">
<P>Same publication as <LINK REF="STD-GETCB-04CB86" TYPE="STUDY">GETCB 04CB86</LINK>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-09-07 11:26:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Italy-2002">
<CHAR_METHODS MODIFIED="2009-02-13 08:50:24 +0000" MODIFIED_BY="[Empty name]">
<P>1989 to 1997</P>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-12 14:24:16 +0000" MODIFIED_BY="[Empty name]">
<P>104 patients<BR/>Stage I</P>
<P>Trial data used in subgroup analyses for age, sex, histology and stage</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-09-07 11:26:48 +0100" MODIFIED_BY="[Empty name]">
<P>Surgery + radiotherapy vs surgery alone<BR/>RT details<BR/>50.4 Gy in 1.8 Gy/d in 5 weeks and 3 days<BR/>Prescription technique: angled field technique machine used: linac<BR/>Average field size (cm): unavailable<BR/>Clinical target volume: bronchial stump, hilum, mediastinum<BR/>Technique: unavailable</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-02-13 08:50:24 +0000" MODIFIED_BY="[Empty name]">
<P>Survival</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-02-06 14:03:33 +0000" MODIFIED_BY="Jenny Bellorini">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-09-07 11:34:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Korea-2007">
<CHAR_METHODS MODIFIED="2009-02-13 08:50:24 +0000" MODIFIED_BY="[Empty name]">
<P>1989 to 1998</P>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-09-07 11:27:05 +0100" MODIFIED_BY="[Empty name]">
<P>111 patients<BR/>Stages II, III</P>
<P>Trial data used in subgroup analyses for sex, age, histology, stage and nodal status</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-09-07 11:34:33 +0100" MODIFIED_BY="[Empty name]">
<P>Surgery + radiotherapy vs surgery alone<BR/>RT details<BR/>50.4 to 55.8 Gy in 1.8 to 2 Gy fractions, 5 times a week<BR/>Prescription technique: at midplane<BR/>Average field size: defined inferiorly by a point 5 cm below the carina and superiorly by the suprasternal notch<BR/>Clinical target volume: tumour bed, bronchial stump, ipsilateral hilum, vascular shadows of the bilateral mediastinum<BR/>Technique: combination of parallel opposed, and anterior and posterior oblique fields, or any combination chosen at the discretion of the chest radiation oncologist</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-02-13 08:50:24 +0000" MODIFIED_BY="[Empty name]">
<P>Survival</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-02-13 08:50:24 +0000" MODIFIED_BY="[Empty name]">
<P>Abstract only</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-09-07 11:27:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-LCSG-773">
<CHAR_METHODS MODIFIED="2009-02-13 08:50:24 +0000" MODIFIED_BY="[Empty name]">
<P>1978 to 1985</P>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-09-07 11:27:38 +0100" MODIFIED_BY="[Empty name]">
<P>230 patients<BR/>Stages II, III</P>
<P>Trial data used in subgroup analyses for sex, age, histology, stage and nodal status</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-09-07 11:27:40 +0100" MODIFIED_BY="[Empty name]">
<P>Surgery + radiotherapy vs surgery alone<BR/>RT details<BR/>50 Gy in 25 to 27.5 fractions in 5 to 5.5 weeks<BR/>Prescription technique: central axis, at midplane<BR/>Machine used: Co60 and linac<BR/>Average field size (cm): unavailable<BR/>Clinical target volume: bronchial stump, hilum, mediastinum<BR/>Technique: spinal cord blocks, oblique fields, lateral fields</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-02-13 08:50:24 +0000" MODIFIED_BY="[Empty name]">
<P>Survival</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-02-13 08:50:24 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-09-07 11:27:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lille-1985">
<CHAR_METHODS MODIFIED="2009-02-13 08:50:24 +0000" MODIFIED_BY="[Empty name]">
<P>1985 to 1991</P>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-02-13 08:50:24 +0000" MODIFIED_BY="[Empty name]">
<P>163 patients<BR/>Stage I</P>
<P>Trial data used in subgroup analyses for sex, age, histology, stage and nodal status</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-09-07 11:27:55 +0100" MODIFIED_BY="[Empty name]">
<P>Surgery + radiotherapy vs surgery alone<BR/>RT details<BR/>45 to 60 Gy in 22.5 to 30 fractions in 6 weeks<BR/>Prescription technique: isodose 90%<BR/>Machine used: Co60 and linac<BR/>Average field size (cm): 12 × 12<BR/>Clinical target volume: hilum, upper mediastinum<BR/>Technique: spinal cord blocks, oblique fields, lateral fields</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-02-13 08:50:24 +0000" MODIFIED_BY="[Empty name]">
<P>Survival</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-02-13 08:50:24 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-09-07 11:28:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-MRC-LU11">
<CHAR_METHODS MODIFIED="2009-02-13 08:50:25 +0000" MODIFIED_BY="[Empty name]">
<P>1986 to 1993</P>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-09-07 11:28:09 +0100" MODIFIED_BY="[Empty name]">
<P>308 patients<BR/>Stages II, III</P>
<P>Trial data used in subgroup analyses for sex, age, histology, stage and nodal status</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-09-07 11:28:15 +0100" MODIFIED_BY="[Empty name]">
<P>Surgery + radiotherapy vs surgery alone<BR/>RT details<BR/>40 Gy in 15 fractions in 3 weeks<BR/>Prescription technique: central axis, at midplane<BR/>Machine used: Co60 and linac<BR/>Average field size (cm): unavailable<BR/>Clinical target volume: hilum, mediastinum, supraclavicular fossae for upper lobes<BR/>Technique: spinal cord blocks, oblique fields, lateral fields</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-02-13 08:50:25 +0000" MODIFIED_BY="[Empty name]">
<P>Survival</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-02-13 08:50:25 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-09-07 11:34:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Slovenia-1988">
<CHAR_METHODS MODIFIED="2009-02-13 08:50:25 +0000" MODIFIED_BY="[Empty name]">
<P>1988 to 1992 RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-02-13 08:50:25 +0000" MODIFIED_BY="[Empty name]">
<P>74 patients<BR/>Stage III</P>
<P>Trial data used in subgroup analyses for sex, age, histology, stage and nodal status</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-09-07 11:34:33 +0100" MODIFIED_BY="[Empty name]">
<P>Surgery + radiotherapy vs surgery alone<BR/>RT details<BR/>30 Gy in 10 to 12 fractions in 2 weeks<BR/>Prescription technique: central axis, at the midplane<BR/>Machine used: linac<BR/>Average field size (cm): 9 × 12<BR/>Clinical target volume: hilum, mediastinum<BR/>Technique: oblique fields, lateral fields</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-02-13 08:50:25 +0000" MODIFIED_BY="[Empty name]">
<P>Survival</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-02-13 08:50:25 +0000" MODIFIED_BY="[Empty name]">
<P>Sealed envelope randomisation</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>All trials supplied individual participant data for analysis and therefore are defined as unpublished data, even though most are published.</P>
<P>IPD = individual participant data.<BR/>RCT = randomised controlled trial.<BR/>RT = radiotherapy.1G</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2016-09-07 11:32:43 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2016-09-07 11:32:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Austria-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-09-07 11:32:38 +0100" MODIFIED_BY="[Empty name]">
<P>Data unavailable/eligibility uncertain<BR/>Reported to be an RCT. Data provided by trialists, but anomalies evident between reported results and data received, and it was not clear if the trial was randomised. We were unable to resolve these problems with the trialists</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-09-07 11:32:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dymek-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-09-07 11:32:40 +0100" MODIFIED_BY="[Empty name]">
<P>Eligible<BR/>Data could not be obtained</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-09-07 11:32:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-LCSG-841">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-09-07 11:32:42 +0100" MODIFIED_BY="[Empty name]">
<P>Eligible<BR/>Data could not be obtained (5 participants)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>RCT = randomised controlled trial.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2009-01-19 18:44:53 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2016-09-07 11:32:44 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2016-09-07 11:32:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lung-ART_x002d_IGR-2006_x002f_1202">
<CHAR_STUDY_NAME MODIFIED="2016-07-20 10:18:02 +0100" MODIFIED_BY="[Empty name]">
<P>Essai de phase III comparant une radiothérapie médiastinale conformationnelle post-opératoire à l&#8217;absence de radiothérapie après chirurgie complète chez des patients présentant un carcinome bronchique non à petites cellules (CBNPC) avec envahissement médiastinal N2</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2016-09-07 11:32:44 +0100" MODIFIED_BY="[Empty name]">
<P>Phase III multi-centric</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES MODIFIED="2016-07-20 10:18:45 +0100" MODIFIED_BY="[Empty name]">
<P>Evaluation de l&#8217;impact de la radiothérapie médiastinale conformationnelle sur la survie sans récidive comparé à l&#8217;absence de radiothérapie</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2016-07-20 10:20:36 +0100" MODIFIED_BY="[Empty name]">
<P>2006</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2016-07-20 10:20:15 +0100" MODIFIED_BY="[Empty name]">
<P>Docteur Cécile Le Péchoux - lepechoux@igr.fr</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2016-09-07 11:34:33 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2016-09-07 11:31:51 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 11:23:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Belgium-1966">
<DESCRIPTION>
<P>Comment: stated as randomised in paper; checks run on IPD suggest adequate sequence generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 11:23:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-CAMS-1981">
<DESCRIPTION>
<P>Comment: stated as randomised in paper; checks run on IPD suggest adequate sequence generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 11:24:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-EORTC-08861">
<DESCRIPTION>
<P>Comment: unpublished trial; checks run on IPD suggest adequate sequence generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 11:25:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-GETCB-04CB86">
<DESCRIPTION>
<P>Quote: "randomly assigned by centralised telephone procedure"</P>
<P>Comment: stated as randomised in paper; checks run on IPD suggest adequate sequence generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 11:26:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-GETCB-05CB88">
<DESCRIPTION>
<P>Quote: "randomly assigned by centralised telephone procedure"</P>
<P>Comment: stated as randomised in paper; checks run on IPD suggest adequate sequence generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 11:26:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Italy-2002">
<DESCRIPTION>
<P>Quote: "by chance" using computer-generated model</P>
<P>Comment: stated as randomised in paper; checks run on IPD suggest adequate sequence generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 11:27:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Korea-2007">
<DESCRIPTION>
<P>Comment: stated as randomised in paper; checks run on IPD suggest adequate sequence generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 11:27:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-LCSG-773">
<DESCRIPTION>
<P>Quote: "permuted block randomisation"</P>
<P>Comment: stated as randomised in paper; checks run on IPD suggest adequate sequence generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 11:27:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lille-1985">
<DESCRIPTION>
<P>Quote: "randomised with a table of randomisation according to Snedecor and Cochran"</P>
<P>Comment: stated as randomised in paper; checks run on IPD suggest adequate sequence generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 11:28:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-MRC-LU11">
<DESCRIPTION>
<P>Comment: stated as randomised in paper; checks run on IPD suggest adequate sequence generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 11:31:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Slovenia-1988">
<DESCRIPTION>
<P>Comment: stated as randomised in paper; checks run on IPD suggest adequate sequence generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2016-09-07 11:27:58 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-13 08:50:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Belgium-1966">
<DESCRIPTION>
<P>Quote: "randomisation carried out via sealed envelope"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-13 08:50:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-CAMS-1981">
<DESCRIPTION>
<P>Quote: "randomisation carried out via sealed envelope"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 11:24:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-EORTC-08861">
<DESCRIPTION>
<P>Comment: unpublished, insufficient information provided, but collection of IPD and correspondence with those who supplied the data reassured that data were adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 11:25:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-GETCB-04CB86">
<DESCRIPTION>
<P>Comment: randomisation by central telephone call</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 11:26:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-GETCB-05CB88">
<DESCRIPTION>
<P>Comment: randomisation by central telephone call</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 11:26:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Italy-2002">
<DESCRIPTION>
<P>Comment: computer-generated randomisation, which was checked by an independent colleague</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 11:27:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Korea-2007">
<DESCRIPTION>
<P>Comment: insufficient information provided in abstract, but collection of IPD and correspondence with those who supplied the data reassured that data were adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-19 18:10:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-LCSG-773">
<DESCRIPTION>
<P>Quote: treatment assigned by central office</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 11:27:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lille-1985">
<DESCRIPTION>
<P>Quote: "randomised with a table of randomisation according to Snedecor and Cochran"; insufficient information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-13 08:50:25 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-MRC-LU11">
<DESCRIPTION>
<P>Quote: "treatment assigned by central office"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-13 08:50:25 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Slovenia-1988">
<DESCRIPTION>
<P>Quote: "randomisation carried out via sealed envelope"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2016-09-07 11:34:33 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-09-07 11:23:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Belgium-1966">
<DESCRIPTION>
<P>Comment: trial not blinded owing to the nature of the intervention; outcome not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-09-07 11:34:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-CAMS-1981">
<DESCRIPTION>
<P>Comment: trial not blinded owing to the nature of the intervention; outcome not likely influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-09-07 11:25:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-EORTC-08861">
<DESCRIPTION>
<P>Comment: trial not blinded owing to the nature of the intervention; outcome not likely influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-09-07 11:34:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-GETCB-04CB86">
<DESCRIPTION>
<P>Comment: trial not blinded owing to the nature of the intervention; outcome not likely influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-09-07 11:26:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-GETCB-05CB88">
<DESCRIPTION>
<P>Comment: trial not blinded owing to the nature of the intervention; outcome not likely influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-09-07 11:27:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Italy-2002">
<DESCRIPTION>
<P>Comment: trial not blinded owing to the nature of the intervention; outcome not likely influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-09-07 11:27:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Korea-2007">
<DESCRIPTION>
<P>Comment: trial not blinded owing to the nature of the intervention; outcome not likely influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-09-07 11:27:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-LCSG-773">
<DESCRIPTION>
<P>Comment: trial not blinded owing to the nature of intervention; outcome not likely influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-09-07 11:34:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lille-1985">
<DESCRIPTION>
<P>Comment: trial not blinded owing to the nature of the intervention; outcome not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-09-07 11:31:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-MRC-LU11">
<DESCRIPTION>
<P>Comment: trial not blinded owing to the nature of the intervention; outcome not likely influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-09-07 11:31:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Slovenia-1988">
<DESCRIPTION>
<P>Comment: trial not blinded owing to the nature of the intervention; outcome not likely influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2016-09-07 11:24:01 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-11 15:01:34 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Belgium-1966">
<DESCRIPTION>
<P>Comment: individual participant data obtained and checked for all outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-09-07 11:24:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-CAMS-1981">
<DESCRIPTION>
<P>Comment: individual participant data obtained and checked for all outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-11 15:01:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-EORTC-08861">
<DESCRIPTION>
<P>Comment: individual participant data obtained and checked for all outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-11 15:02:05 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-GETCB-04CB86">
<DESCRIPTION>
<P>Comment: individual participant data obtained and checked for all outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-11 15:02:14 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-GETCB-05CB88">
<DESCRIPTION>
<P>Comment: individual participant data obtained and checked for all outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-11 15:02:23 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Italy-2002">
<DESCRIPTION>
<P>Comment: individual participant data obtained and checked for all outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-11 15:02:36 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Korea-2007">
<DESCRIPTION>
<P>Comment: individual participant data obtained and checked for all outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-11 15:02:44 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-LCSG-773">
<DESCRIPTION>
<P>Comment: individual participant data obtained and checked for all outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-11 15:02:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lille-1985">
<DESCRIPTION>
<P>Comment: individual participant data obtained and checked for all outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-11 15:03:11 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-MRC-LU11">
<DESCRIPTION>
<P>Comment: individual participant data obtained and checked for all outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-11 15:03:27 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Slovenia-1988">
<DESCRIPTION>
<P>Comment: individual participant data obtained and checked for all outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2016-09-07 11:34:33 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-11 15:01:37 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Belgium-1966">
<DESCRIPTION>
<P>Comment: individual participant data obtained and checked for all outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 11:34:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-CAMS-1981">
<DESCRIPTION>
<P>Comment: individual participant data obtained and checked for all outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-11 15:01:58 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-EORTC-08861">
<DESCRIPTION>
<P>Comment: individual participant data obtained and checked for all outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-11 15:02:08 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-GETCB-04CB86">
<DESCRIPTION>
<P>Comment: individual participant data obtained and checked for all outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-11 15:02:17 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-GETCB-05CB88">
<DESCRIPTION>
<P>Comment: individual participant data obtained and checked for all outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-11 15:02:27 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Italy-2002">
<DESCRIPTION>
<P>Comment: individual participant data obtained and checked for all outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-11 15:02:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Korea-2007">
<DESCRIPTION>
<P>Comment: individual participant data obtained and checked for all outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-11 15:02:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-LCSG-773">
<DESCRIPTION>
<P>Comment: individual participant data obtained and checked for all outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-11 15:02:58 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lille-1985">
<DESCRIPTION>
<P>Comment: individual participant data obtained and checked for all outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-11 15:03:20 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-MRC-LU11">
<DESCRIPTION>
<P>Comment: individual participant data obtained and checked for all outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-11 15:03:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Slovenia-1988">
<DESCRIPTION>
<P>Comment: individual participant data obtained and checked for all outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2016-09-07 11:34:33 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 11:23:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Belgium-1966">
<DESCRIPTION>
<P>Comment: study apparently free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 11:24:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-CAMS-1981">
<DESCRIPTION>
<P>Comment: study apparently free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 11:25:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-EORTC-08861">
<DESCRIPTION>
<P>Comment: study apparently free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 11:25:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-GETCB-04CB86">
<DESCRIPTION>
<P>Comment: study apparently free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 11:26:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-GETCB-05CB88">
<DESCRIPTION>
<P>Comment: study apparently free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 11:34:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Italy-2002">
<DESCRIPTION>
<P>Comment: study apparently free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 11:27:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Korea-2007">
<DESCRIPTION>
<P>Comment: study apparently free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 11:27:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-LCSG-773">
<DESCRIPTION>
<P>Comment: study apparently free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 11:28:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lille-1985">
<DESCRIPTION>
<P>Comment: study apparently free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 11:31:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-MRC-LU11">
<DESCRIPTION>
<P>Comment: study apparently free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 11:32:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Slovenia-1988">
<DESCRIPTION>
<P>Comment: study apparently free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2008-11-18 17:33:31 +0000" MODIFIED_BY="[Empty name]"/>
<ADDITIONAL_TABLES MODIFIED="2016-09-13 11:20:13 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2016-09-07 11:32:48 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2013-11-12 14:28:56 +0000" MODIFIED_BY="[Empty name]">Common meta-analysis stage scale (original analyses - based on TNM 4th edition)</TITLE>
<TABLE COLS="5" ROWS="6">
<TR>
<TH VALIGN="BOTTOM">
<P>T stage</P>
</TH>
<TH VALIGN="BOTTOM">
<P>N stage</P>
</TH>
<TH VALIGN="BOTTOM">
<P>M stage</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Meta-analysis stage</P>
</TH>
<TH VALIGN="BOTTOM">
<P>AJCC stage</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>0, 1, 2, X, iS</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>I</P>
</TD>
<TD VALIGN="TOP">
<P>I</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>0, 1, 2, X, iS</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>II</P>
</TD>
<TD VALIGN="TOP">
<P>II</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Any</P>
</TD>
<TD VALIGN="TOP">
<P>2, 3</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>III</P>
</TD>
<TD VALIGN="TOP">
<P>III non-metastatic</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3, 4</P>
</TD>
<TD VALIGN="TOP">
<P>Any</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>III</P>
</TD>
<TD VALIGN="TOP">
<P>III non-metastatic</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Any</P>
</TD>
<TD VALIGN="TOP">
<P>Any</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>IV</P>
</TD>
<TD VALIGN="TOP">
<P>Any metastatic</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>AJCC = American Joint Committee on Cancer.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2016-09-07 11:36:20 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2016-09-07 11:36:20 +0100" MODIFIED_BY="[Empty name]">Common meta-analysis stage scale (current analysis - based on TNM 6th edition)</TITLE>
<TABLE COLS="4" ROWS="7">
<TR>
<TD VALIGN="BOTTOM">
<P>
<B>T stage</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
<P>
<B>N stage</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
<P>
<B>M stage</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
<P>
<B>Meta-analysis stage</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>1, 2</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>I</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>1, 2</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>II</P>
</TD>
</TR>
<TR>
<TD>
<P>3</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>II</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>1, 2</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>III</P>
</TD>
</TR>
<TR>
<TD>
<P>3</P>
</TD>
<TD>
<P>1, 2</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>III</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Any</P>
</TD>
<TD VALIGN="TOP">
<P>Any</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>IV</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2016-09-07 11:36:48 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2016-09-07 11:36:48 +0100" MODIFIED_BY="[Empty name]">Characteristics of participants in PORT meta-analysis</TITLE>
<TABLE COLS="4" ROWS="26">
<TR>
<TH VALIGN="BOTTOM">
<P>Characteristic</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Postoperative RT</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Surgery only</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Total</P>
</TH>
</TR>
<TR>
<TD COLSPAN="4" VALIGN="TOP">
<P>
<B>AGE (data from 11 trials)</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>&lt; 54 years</P>
</TD>
<TD VALIGN="TOP">
<P>294</P>
</TD>
<TD VALIGN="TOP">
<P>327</P>
</TD>
<TD VALIGN="TOP">
<P>621</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>55 to 59 years</P>
</TD>
<TD VALIGN="TOP">
<P>267</P>
</TD>
<TD VALIGN="TOP">
<P>261</P>
</TD>
<TD VALIGN="TOP">
<P>528</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>60 to 64 years</P>
</TD>
<TD VALIGN="TOP">
<P>290</P>
</TD>
<TD VALIGN="TOP">
<P>276</P>
</TD>
<TD VALIGN="TOP">
<P>566</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>&gt; 65 years</P>
</TD>
<TD VALIGN="TOP">
<P>312</P>
</TD>
<TD VALIGN="TOP">
<P>315</P>
</TD>
<TD VALIGN="TOP">
<P>627</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Unknown</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4" VALIGN="TOP">
<P>
<B>SEX (data from 11 trials)</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Male</P>
</TD>
<TD VALIGN="TOP">
<P>988</P>
</TD>
<TD VALIGN="TOP">
<P>992</P>
</TD>
<TD VALIGN="TOP">
<P>1980</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Female</P>
</TD>
<TD VALIGN="TOP">
<P>175</P>
</TD>
<TD VALIGN="TOP">
<P>187</P>
</TD>
<TD VALIGN="TOP">
<P>362</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Not recorded</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4" VALIGN="TOP">
<P>
<B>HISTOLOGY (data from 9 trials)</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Adenocarcinoma</P>
</TD>
<TD VALIGN="TOP">
<P>195</P>
</TD>
<TD VALIGN="TOP">
<P>218</P>
</TD>
<TD VALIGN="TOP">
<P>413</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Squamous</P>
</TD>
<TD VALIGN="TOP">
<P>522</P>
</TD>
<TD VALIGN="TOP">
<P>545</P>
</TD>
<TD VALIGN="TOP">
<P>1067</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Other</P>
</TD>
<TD VALIGN="TOP">
<P>66</P>
</TD>
<TD VALIGN="TOP">
<P>54</P>
</TD>
<TD VALIGN="TOP">
<P>120</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Unknown</P>
</TD>
<TD VALIGN="TOP">
<P>380</P>
</TD>
<TD VALIGN="TOP">
<P>363</P>
</TD>
<TD VALIGN="TOP">
<P>743</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4" VALIGN="TOP">
<P>
<B>META-ANALYSIS STAGE (data from 11 trials)</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>I</P>
</TD>
<TD VALIGN="TOP">
<P>328</P>
</TD>
<TD VALIGN="TOP">
<P>338</P>
</TD>
<TD VALIGN="TOP">
<P>666</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>II</P>
</TD>
<TD VALIGN="TOP">
<P>353</P>
</TD>
<TD VALIGN="TOP">
<P>366</P>
</TD>
<TD VALIGN="TOP">
<P>719</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>III</P>
</TD>
<TD VALIGN="TOP">
<P>463</P>
</TD>
<TD VALIGN="TOP">
<P>455</P>
</TD>
<TD VALIGN="TOP">
<P>918</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>IV</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Unknown</P>
</TD>
<TD VALIGN="TOP">
<P>18</P>
</TD>
<TD VALIGN="TOP">
<P>21</P>
</TD>
<TD VALIGN="TOP">
<P>39</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4" VALIGN="TOP">
<P>
<B>WHO PERFORMANCE STATUS (data from 4 trials; not used)</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Good (0, 1)</P>
</TD>
<TD VALIGN="TOP">
<P>195</P>
</TD>
<TD VALIGN="TOP">
<P>196</P>
</TD>
<TD VALIGN="TOP">
<P>391</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Poor (2, 3, 4)</P>
</TD>
<TD VALIGN="TOP">
<P>77</P>
</TD>
<TD VALIGN="TOP">
<P>83</P>
</TD>
<TD VALIGN="TOP">
<P>160</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Unknown</P>
</TD>
<TD VALIGN="TOP">
<P>22</P>
</TD>
<TD VALIGN="TOP">
<P>21</P>
</TD>
<TD VALIGN="TOP">
<P>43</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" MODIFIED="2016-09-13 11:20:13 +0100" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2016-09-07 11:36:57 +0100" MODIFIED_BY="[Empty name]">Changes in results over time</TITLE>
<TABLE COLS="5" ROWS="6">
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Trend or interaction</P>
<P>1998</P>
</TD>
<TD>
<P>Trend or interaction</P>
<P>2005</P>
</TD>
<TD>
<P>Trend or interaction</P>
<P>2010 'old' methods</P>
</TD>
<TD>
<P>Trend or interaction</P>
<P>2010 'new' methods</P>
<P>and TNM changes</P>
</TD>
</TR>
<TR>
<TD>
<P>Age</P>
</TD>
<TD>
<P>P = 0.34</P>
</TD>
<TD>
<P>P = 0.44</P>
</TD>
<TD>
<P>P = 0.32</P>
</TD>
<TD>
<P>P = 0.20</P>
</TD>
</TR>
<TR>
<TD>
<P>Sex</P>
</TD>
<TD>
<P>P = 0.94</P>
</TD>
<TD>
<P>P = 0.92</P>
</TD>
<TD>
<P>P = 0.84</P>
</TD>
<TD>
<P>P = 0.49</P>
</TD>
</TR>
<TR>
<TD>
<P>Histology</P>
</TD>
<TD>
<P>P = 0.75</P>
</TD>
<TD>
<P>P = 0.61</P>
</TD>
<TD>
<P>P = 0.42</P>
</TD>
<TD>
<P>P = 0.38</P>
</TD>
</TR>
<TR>
<TD>
<P>Stage</P>
</TD>
<TD>
<P>P = 0.0003</P>
</TD>
<TD>
<P>P = 0.003</P>
</TD>
<TD>
<P>P = 0.003</P>
</TD>
<TD>
<P>P = 0.12</P>
</TD>
</TR>
<TR>
<TD>
<P>Nodal status</P>
</TD>
<TD>
<P>P = 0.016</P>
</TD>
<TD>
<P>P = 0.02</P>
</TD>
<TD>
<P>P = 0.03</P>
</TD>
<TD>
<P>P = 0.39</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2016-09-09 10:26:35 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2016-09-09 10:26:35 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Surgery + PORT versus surgery alone</NAME>
<IPD_OUTCOME CHI2="16.654094958406084" CI_END="1.3066155026152382" CI_START="1.066528202570665" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_SIZE="1.1804839191853467" ESTIMABLE="YES" EVENTS_1="777" EVENTS_2="734" I2="39.95470768615654" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.11614780666284938" LOG_CI_START="0.02797234413506962" LOG_EFFECT_SIZE="0.07206007539895949" MODIFIED="2009-01-19 16:54:16 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.08237711229342348" P_Q="1.0" P_Z="0.0013576691282737529" Q="0.0" SCALE="10.0" SORT_BY="USER" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1163" TOTAL_2="1180" WEIGHT="99.99999999999997" Z="3.2035023907179396">
<NAME>Survival</NAME>
<GROUP_LABEL_1>Surgery + PORT</GROUP_LABEL_1>
<GROUP_LABEL_2>Surgery</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PORT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no PORT</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IPD_DATA CI_END="2.017235848880563" CI_START="1.0909617226750858" EFFECT_SIZE="1.483484781430763" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="80" LOG_CI_END="0.30475667752827656" LOG_CI_START="0.037809513262387726" LOG_EFFECT_SIZE="0.17128309539533218" ORDER="1" O_E="16.04" SE="0.15680608569955762" STUDY_ID="STD-Belgium-1966" TOTAL_1="98" TOTAL_2="104" VAR="40.67" WEIGHT="10.910505419036378"/>
<IPD_DATA CI_END="1.5254738113665507" CI_START="0.8271778278213889" EFFECT_SIZE="1.1233156785537175" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="81" LOG_CI_END="0.18340475627431357" LOG_CI_START="-0.0824011151880868" LOG_EFFECT_SIZE="0.05050182054311342" ORDER="2" O_E="4.77" SE="0.15613568465729805" STUDY_ID="STD-LCSG-773" TOTAL_1="110" TOTAL_2="120" VAR="41.02" WEIGHT="11.004399613692456"/>
<IPD_DATA CI_END="1.3721870877704996" CI_START="0.7643548212494584" EFFECT_SIZE="1.0241278319592897" ESTIMABLE="YES" EVENTS_1="83" EVENTS_2="100" LOG_CI_END="0.13741332831468508" LOG_CI_START="-0.11670499071947658" LOG_EFFECT_SIZE="0.010354168797604247" ORDER="3" O_E="1.07" SE="0.14927035850663303" STUDY_ID="STD-CAMS-1981" TOTAL_1="153" TOTAL_2="164" VAR="44.88" WEIGHT="12.039918446185213"/>
<IPD_DATA CI_END="2.249111532816738" CI_START="1.037379460389167" EFFECT_SIZE="1.5274757308279827" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="45" LOG_CI_END="0.3520109925124774" LOG_CI_START="0.01593764492231189" LOG_EFFECT_SIZE="0.18397431871739464" ORDER="4" O_E="10.87" SE="0.19741114796436382" STUDY_ID="STD-Lille-1985" TOTAL_1="81" TOTAL_2="82" VAR="25.66" WEIGHT="6.883785813928533"/>
<IPD_DATA CI_END="2.94291697221189" CI_START="0.9121952180847275" EFFECT_SIZE="1.6384488973636226" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="20" LOG_CI_END="0.46877800962972616" LOG_CI_START="-0.03991220875026487" LOG_EFFECT_SIZE="0.21443290043973065" ORDER="5" O_E="5.53" SE="0.2988071523335984" STUDY_ID="STD-EORTC-08861" TOTAL_1="52" TOTAL_2="54" VAR="11.2" WEIGHT="3.004614228994527"/>
<IPD_DATA CI_END="1.2368508587477591" CI_START="0.7437247571719126" EFFECT_SIZE="0.9591019781962963" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="123" LOG_CI_END="0.09231733493403664" LOG_CI_START="-0.12858776144085815" LOG_EFFECT_SIZE="-0.018135213253410727" ORDER="6" O_E="-2.48" SE="0.12976074710847596" STUDY_ID="STD-MRC-LU11" TOTAL_1="154" TOTAL_2="154" VAR="59.39" WEIGHT="15.932503487498657"/>
<IPD_DATA CI_END="1.6576688095456495" CI_START="0.8252887363842315" EFFECT_SIZE="1.169639002929315" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="59" LOG_CI_END="0.21949776592815637" LOG_CI_START="-0.08339408214081245" LOG_EFFECT_SIZE="0.06805184189367196" ORDER="7" O_E="4.95" SE="0.17792017089454126" STUDY_ID="STD-GETCB-04CB86" TOTAL_1="99" TOTAL_2="90" VAR="31.59" WEIGHT="8.474621740530099"/>
<IPD_DATA CI_END="1.3910373132475855" CI_START="0.5160953803809419" EFFECT_SIZE="0.847294477324499" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="33" LOG_CI_END="0.14333877968304953" LOG_CI_START="-0.28727002832405046" LOG_EFFECT_SIZE="-0.07196562432050048" ORDER="8" O_E="-2.59" SE="0.25294174537134734" STUDY_ID="STD-Slovenia-1988" TOTAL_1="35" TOTAL_2="39" VAR="15.63" WEIGHT="4.193046464212898"/>
<IPD_DATA CI_END="1.847682582328463" CI_START="1.144905871912594" EFFECT_SIZE="1.4544492558829551" ESTIMABLE="YES" EVENTS_1="152" EVENTS_2="120" LOG_CI_END="0.2666273648367123" LOG_CI_START="0.05876978275508019" LOG_EFFECT_SIZE="0.1626985737958962" ORDER="9" O_E="25.13" SE="0.12209657262637609" STUDY_ID="STD-GETCB-05CB88" TOTAL_1="274" TOTAL_2="265" VAR="67.08" WEIGHT="17.995493078656505"/>
<IPD_DATA CI_END="1.2195710990480133" CI_START="0.41443698556984343" EFFECT_SIZE="0.710939779431113" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="30" LOG_CI_END="0.0862071240627354" LOG_CI_START="-0.38254149382234626" LOG_EFFECT_SIZE="-0.14816718487980543" ORDER="10" O_E="-4.5" SE="0.2753452584887775" STUDY_ID="STD-Italy-2002" TOTAL_1="51" TOTAL_2="53" VAR="13.19" WEIGHT="3.538469792896233"/>
<IPD_DATA CI_END="1.73318274897865" CI_START="0.757786445721962" EFFECT_SIZE="1.1460289678429383" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="43" LOG_CI_END="0.23884435768713247" LOG_CI_START="-0.12045316707475373" LOG_EFFECT_SIZE="0.05919559530618934" MODIFIED="2008-07-22 09:58:56 +0100" MODIFIED_BY="[Empty name]" ORDER="111" O_E="3.06" SE="0.21105314459656363" STUDY_ID="STD-Korea-2007" TOTAL_1="56" TOTAL_2="55" VAR="22.45" WEIGHT="6.022641914368494"/>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="18.85684284704137" CI_END="1.2349243147508984" CI_START="1.0111294778860758" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_SIZE="1.1174383104238443" ESTIMABLE="YES" EVENTS_1="793" EVENTS_2="763" I2="46.96885326395455" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.09164034164971381" LOG_CI_START="0.004806771744311716" LOG_EFFECT_SIZE="0.04822355669701278" MODIFIED="2015-03-10 12:33:20 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.04211914791229976" P_Q="1.0" P_Z="0.02948384393874503" Q="0.0" SCALE="10.0" SORT_BY="USER" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1163" TOTAL_2="1180" WEIGHT="100.00000000000001" Z="2.176956088193497">
<NAME>Local recurrence-free survival</NAME>
<GROUP_LABEL_1>Surgery + PORT</GROUP_LABEL_1>
<GROUP_LABEL_2>Surgery</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PORT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no PORT</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IPD_DATA CI_END="1.959918632145562" CI_START="1.0609229205099293" EFFECT_SIZE="1.4419856445810044" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="80" LOG_CI_END="0.29223804158927524" LOG_CI_START="0.025683832145245496" LOG_EFFECT_SIZE="0.15896093686726032" ORDER="1" O_E="14.93" SE="0.15657526209203987" STUDY_ID="STD-Belgium-1966" TOTAL_1="98" TOTAL_2="104" VAR="40.79" WEIGHT="10.612170564820357"/>
<IPD_DATA CI_END="1.4780936328592544" CI_START="0.8030943444478887" EFFECT_SIZE="1.0895176167064493" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="81" LOG_CI_END="0.1697019462009533" LOG_CI_START="-0.09523343247184154" LOG_EFFECT_SIZE="0.037234256864555906" ORDER="2" O_E="3.54" SE="0.15562435288367493" STUDY_ID="STD-LCSG-773" TOTAL_1="110" TOTAL_2="120" VAR="41.29" WEIGHT="10.742253557769859"/>
<IPD_DATA CI_END="1.2395874464271182" CI_START="0.7115532742261692" EFFECT_SIZE="0.93916585659556" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="111" LOG_CI_END="0.09327716939441771" LOG_CI_START="-0.1477925785926201" LOG_EFFECT_SIZE="-0.027257704599101238" ORDER="3" O_E="-3.13" SE="0.14160556328208412" STUDY_ID="STD-CAMS-1981" TOTAL_1="153" TOTAL_2="164" VAR="49.87" WEIGHT="12.974477716783309"/>
<IPD_DATA CI_END="2.209325595627223" CI_START="1.0194892761153043" EFFECT_SIZE="1.5007943737198013" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="45" LOG_CI_END="0.3442597240036697" LOG_CI_START="0.008382661846927071" LOG_EFFECT_SIZE="0.17632119292529838" ORDER="4" O_E="10.43" SE="0.19729584892914265" STUDY_ID="STD-Lille-1985" TOTAL_1="81" TOTAL_2="82" VAR="25.69" WEIGHT="6.683664177745403"/>
<IPD_DATA CI_END="2.26259720552109" CI_START="0.7311101838434408" EFFECT_SIZE="1.28616012179362" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="23" LOG_CI_END="0.35460724640301794" LOG_CI_START="-0.1360171666410822" LOG_EFFECT_SIZE="0.10929503988096786" ORDER="5" O_E="3.03" SE="0.28819520885211747" STUDY_ID="STD-EORTC-08861" TOTAL_1="52" TOTAL_2="54" VAR="12.04" WEIGHT="3.132398470224003"/>
<IPD_DATA CI_END="1.2478178678319132" CI_START="0.753530545159879" EFFECT_SIZE="0.9696746249168426" ESTIMABLE="YES" EVENTS_1="118" EVENTS_2="125" LOG_CI_END="0.09615120011566612" LOG_CI_START="-0.12289913840507172" LOG_EFFECT_SIZE="-0.01337396914470279" ORDER="6" O_E="-1.86" SE="0.1286712531637447" STUDY_ID="STD-MRC-LU11" TOTAL_1="154" TOTAL_2="154" VAR="60.4" WEIGHT="15.714025548299816"/>
<IPD_DATA CI_END="1.4691846141571232" CI_START="0.7364790125509136" EFFECT_SIZE="1.040203650200014" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="61" LOG_CI_END="0.16707637160515867" LOG_CI_START="-0.1328396247387943" LOG_EFFECT_SIZE="0.01711837343318219" MODIFIED="2009-02-13 08:56:03 +0000" MODIFIED_BY="[Empty name]" ORDER="7" O_E="1.27" SE="0.17617214086056332" STUDY_ID="STD-GETCB-04CB86" TOTAL_1="99" TOTAL_2="90" VAR="32.22" WEIGHT="8.382548065665896"/>
<IPD_DATA CI_END="1.5481347358521882" CI_START="0.5751086433930049" EFFECT_SIZE="0.9435812989486068" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="33" LOG_CI_END="0.1898087551134967" LOG_CI_START="-0.24025010527711627" LOG_EFFECT_SIZE="-0.02522067508180976" ORDER="8" O_E="-0.91" SE="0.2526187034191383" STUDY_ID="STD-Slovenia-1988" TOTAL_1="35" TOTAL_2="39" VAR="15.67" WEIGHT="4.076800999037386"/>
<IPD_DATA CI_END="1.7512365626975397" CI_START="1.0957796546584024" EFFECT_SIZE="1.3852687089145839" ESTIMABLE="YES" EVENTS_1="156" EVENTS_2="127" LOG_CI_END="0.24334481594910634" LOG_CI_START="0.03972323262760541" LOG_EFFECT_SIZE="0.14153402428835593" MODIFIED="2009-02-13 08:57:19 +0000" MODIFIED_BY="[Empty name]" ORDER="9" O_E="22.78" SE="0.11960832598614295" STUDY_ID="STD-GETCB-05CB88" TOTAL_1="274" TOTAL_2="265" VAR="69.9" WEIGHT="18.18560241434035"/>
<IPD_DATA CI_END="0.9286486815399845" CI_START="0.32646522825197616" EFFECT_SIZE="0.5506101195808589" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="34" LOG_CI_END="-0.03214855352573443" LOG_CI_START="-0.48616306854656766" LOG_EFFECT_SIZE="-0.25915581103615104" MODIFIED="2015-03-10 12:33:20 +0000" MODIFIED_BY="[Empty name]" ORDER="10" O_E="-8.39" SE="0.26669037353133246" STUDY_ID="STD-Italy-2002" TOTAL_1="51" TOTAL_2="53" VAR="14.06" WEIGHT="3.6579337617399905"/>
<IPD_DATA CI_END="1.5806977579215216" CI_START="0.6909892072450797" EFFECT_SIZE="1.0451053012210143" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="43" LOG_CI_END="0.19884883728498454" LOG_CI_START="-0.16052873594057993" LOG_EFFECT_SIZE="0.019160050672202292" MODIFIED="2008-07-22 10:03:18 +0100" MODIFIED_BY="[Empty name]" ORDER="113" O_E="0.99" SE="0.21110016546037452" STUDY_ID="STD-Korea-2007" TOTAL_1="56" TOTAL_2="55" VAR="22.44" WEIGHT="5.838124723573641"/>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="14.510174984903923" CI_END="1.2438964368921763" CI_START="1.0193786139398104" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_SIZE="1.126055693881886" ESTIMABLE="YES" EVENTS_1="799" EVENTS_2="771" I2="31.08284351909066" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.0947842237964998" LOG_CI_START="0.008335518064385799" LOG_EFFECT_SIZE="0.051559870930442814" MODIFIED="2013-11-04 11:00:46 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.15096653503774793" P_Q="1.0" P_Z="0.019390905185895778" Q="0.0" SCALE="10.0" SORT_BY="USER" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1163" TOTAL_2="1180" WEIGHT="100.0" Z="2.337929508958779">
<NAME>Distant recurrence-free survival</NAME>
<GROUP_LABEL_1>Surgery + PORT</GROUP_LABEL_1>
<GROUP_LABEL_2>Surgery</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PORT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no PORT</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IPD_DATA CI_END="2.037522154013057" CI_START="1.100931954837036" EFFECT_SIZE="1.4977226872960705" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="80" LOG_CI_END="0.30910233952897903" LOG_CI_START="0.04176047741678004" LOG_EFFECT_SIZE="0.1754314084728795" ORDER="1" O_E="16.38" SE="0.15703793316826603" STUDY_ID="STD-Belgium-1966" TOTAL_1="98" TOTAL_2="104" VAR="40.55" WEIGHT="10.456420835482206"/>
<IPD_DATA CI_END="1.4774787584054374" CI_START="0.808086712598387" EFFECT_SIZE="1.092671475244868" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="84" LOG_CI_END="0.16952124578096175" LOG_CI_START="-0.09254203429668872" LOG_EFFECT_SIZE="0.03848960574213651" MODIFIED="2009-02-13 08:58:23 +0000" MODIFIED_BY="[Empty name]" ORDER="2" O_E="3.74" SE="0.1539372679517698" STUDY_ID="STD-LCSG-773" TOTAL_1="110" TOTAL_2="120" VAR="42.2" WEIGHT="10.881897885507994"/>
<IPD_DATA CI_END="1.2785570663789492" CI_START="0.72869538902872" EFFECT_SIZE="0.9652350174337996" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="108" LOG_CI_END="0.10672011684446832" LOG_CI_START="-0.1374539785549638" LOG_EFFECT_SIZE="-0.015366930855247736" ORDER="3" O_E="-1.72" SE="0.14342907231889207" STUDY_ID="STD-CAMS-1981" TOTAL_1="153" TOTAL_2="164" VAR="48.61" WEIGHT="12.534811758638472"/>
<IPD_DATA CI_END="2.2291937013931515" CI_START="1.032200965512693" EFFECT_SIZE="1.5168967963882134" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="45" LOG_CI_END="0.3481478072829324" LOG_CI_START="0.013764260969777467" LOG_EFFECT_SIZE="0.18095603412635494" ORDER="4" O_E="10.8" SE="0.19641855032959654" STUDY_ID="STD-Lille-1985" TOTAL_1="81" TOTAL_2="82" VAR="25.92" WEIGHT="6.6838576585869"/>
<IPD_DATA CI_END="2.62020635580967" CI_START="0.8623099206339551" EFFECT_SIZE="1.5031400249886309" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="23" LOG_CI_END="0.4183354957702612" LOG_CI_START="-0.06433661743433088" LOG_EFFECT_SIZE="0.1769994391679652" MODIFIED="2009-02-13 08:58:34 +0000" MODIFIED_BY="[Empty name]" ORDER="5" O_E="5.07" SE="0.28352398856187133" STUDY_ID="STD-EORTC-08861" TOTAL_1="52" TOTAL_2="54" VAR="12.44" WEIGHT="3.207839092315626"/>
<IPD_DATA CI_END="1.2184341635345501" CI_START="0.7348927484181361" EFFECT_SIZE="0.9462655183437988" ESTIMABLE="YES" EVENTS_1="118" EVENTS_2="124" LOG_CI_END="0.08580206763144031" LOG_CI_START="-0.13377603801636112" LOG_EFFECT_SIZE="-0.023986985192460418" ORDER="6" O_E="-3.32" SE="0.12898126618667127" STUDY_ID="STD-MRC-LU11" TOTAL_1="154" TOTAL_2="154" VAR="60.11" WEIGHT="15.500257864878803"/>
<IPD_DATA CI_END="1.5319470146349425" CI_START="0.7718574570646886" EFFECT_SIZE="1.0874027437311202" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="61" LOG_CI_END="0.18524374463757343" LOG_CI_START="-0.11246289568253313" LOG_EFFECT_SIZE="0.036390424477520215" ORDER="7" O_E="2.74" SE="0.17487435419566724" STUDY_ID="STD-GETCB-04CB86" TOTAL_1="99" TOTAL_2="90" VAR="32.7" WEIGHT="8.432181536874678"/>
<IPD_DATA CI_END="1.4315668607965377" CI_START="0.5313008528693505" EFFECT_SIZE="0.8721196558275127" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="33" LOG_CI_END="0.15581163639317028" LOG_CI_START="-0.2746594869395845" LOG_EFFECT_SIZE="-0.05942392527320709" ORDER="8" O_E="-2.14" SE="0.2528608687120868" STUDY_ID="STD-Slovenia-1988" TOTAL_1="35" TOTAL_2="39" VAR="15.64" WEIGHT="4.033006704486849"/>
<IPD_DATA CI_END="1.5953629415158428" CI_START="1.009038771694722" EFFECT_SIZE="1.2687722659777934" ESTIMABLE="YES" EVENTS_1="158" EVENTS_2="138" LOG_CI_END="0.20285949966074038" LOG_CI_START="0.003907854056104138" LOG_EFFECT_SIZE="0.10338367685842223" MODIFIED="2009-02-13 08:59:06 +0000" MODIFIED_BY="[Empty name]" ORDER="9" O_E="17.43" SE="0.11686518145469219" STUDY_ID="STD-GETCB-05CB88" TOTAL_1="274" TOTAL_2="265" VAR="73.22" WEIGHT="18.880866425992778"/>
<IPD_DATA CI_END="1.2286201687734226" CI_START="0.4222469589312021" EFFECT_SIZE="0.7202646249442757" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="31" LOG_CI_END="0.08941764033004403" LOG_CI_START="-0.37443346958206675" LOG_EFFECT_SIZE="-0.1425079146260113" ORDER="10" O_E="-4.42" SE="0.27246843806239895" STUDY_ID="STD-Italy-2002" TOTAL_1="51" TOTAL_2="53" VAR="13.47" WEIGHT="3.4734399174832387"/>
<IPD_DATA CI_END="1.6059748861685328" CI_START="0.7084337583593437" EFFECT_SIZE="1.0666427820217474" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="44" LOG_CI_END="0.20573874960785263" LOG_CI_START="-0.1497007519429169" LOG_EFFECT_SIZE="0.02801899883246787" MODIFIED="2008-07-22 10:06:43 +0100" MODIFIED_BY="[Empty name]" ORDER="114" O_E="1.48" SE="0.20878692266483082" STUDY_ID="STD-Korea-2007" TOTAL_1="56" TOTAL_2="55" VAR="22.94" WEIGHT="5.9154203197524495"/>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="17.78853895365871" CI_END="1.210997123286739" CI_START="0.9941458704909365" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_SIZE="1.097227318877868" ESTIMABLE="YES" EVENTS_1="810" EVENTS_2="787" I2="43.78402843509966" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.08314311148146744" LOG_CI_START="-0.0025498871305054457" LOG_EFFECT_SIZE="0.04029661217548095" MODIFIED="2015-03-10 12:37:28 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0586372613060806" P_Q="1.0" P_Z="0.06528196399900155" Q="0.0" SCALE="10.0" SORT_BY="USER" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1163" TOTAL_2="1180" WEIGHT="100.00000000000001" Z="1.8433223213614105">
<NAME>Recurrence-free survival</NAME>
<GROUP_LABEL_1>Surgery + PORT</GROUP_LABEL_1>
<GROUP_LABEL_2>Surgery</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PORT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no PORT</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IPD_DATA CI_END="1.9849924044540321" CI_START="1.0736049313202314" EFFECT_SIZE="1.459827946730385" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="80" LOG_CI_END="0.29775884928048796" LOG_CI_START="0.030844497646308842" LOG_EFFECT_SIZE="0.16430167346339836" ORDER="1" O_E="15.39" SE="0.15678681139726622" STUDY_ID="STD-Belgium-1966" TOTAL_1="98" TOTAL_2="104" VAR="40.68" WEIGHT="10.307345377150531"/>
<IPD_DATA CI_END="1.4304894599182814" CI_START="0.7838355827495818" EFFECT_SIZE="1.0588996833657949" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="84" LOG_CI_END="0.1554846621998672" LOG_CI_START="-0.10577502531692312" LOG_EFFECT_SIZE="0.02485481844147206" ORDER="2" O_E="2.43" SE="0.1534652337036732" STUDY_ID="STD-LCSG-773" TOTAL_1="110" TOTAL_2="120" VAR="42.46" WEIGHT="10.758355081460461"/>
<IPD_DATA CI_END="1.1953005153358203" CI_START="0.6920504871792045" EFFECT_SIZE="0.9095099251595381" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="115" LOG_CI_END="0.07747710674390963" LOG_CI_START="-0.15986222128959943" LOG_EFFECT_SIZE="-0.0411925572728449" ORDER="3" O_E="-4.88" SE="0.13941429613550474" STUDY_ID="STD-CAMS-1981" TOTAL_1="153" TOTAL_2="164" VAR="51.45" WEIGHT="13.036207464463985"/>
<IPD_DATA CI_END="2.1876412530903666" CI_START="1.0134116657066434" EFFECT_SIZE="1.4889530436729284" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="45" LOG_CI_END="0.3399761044176234" LOG_CI_START="0.005785899286468393" LOG_EFFECT_SIZE="0.1728810018520459" ORDER="4" O_E="10.33" SE="0.19630498076223551" STUDY_ID="STD-Lille-1985" TOTAL_1="81" TOTAL_2="82" VAR="25.95" WEIGHT="6.575113385866674"/>
<IPD_DATA CI_END="2.4991771301169825" CI_START="0.8246786120151635" EFFECT_SIZE="1.4356245772641651" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="23" LOG_CI_END="0.3977970380016873" LOG_CI_START="-0.08371526868925566" LOG_EFFECT_SIZE="0.15704088465621585" ORDER="5" O_E="4.52" SE="0.282842712474619" STUDY_ID="STD-EORTC-08861" TOTAL_1="52" TOTAL_2="54" VAR="12.5" WEIGHT="3.1672029797045633"/>
<IPD_DATA CI_END="1.250795797153832" CI_START="0.7568039642344058" EFFECT_SIZE="0.9729374171722217" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="125" LOG_CI_END="0.09718641328406667" LOG_CI_START="-0.12101660171115491" LOG_EFFECT_SIZE="-0.0119150942135441" ORDER="6" O_E="-1.67" SE="0.1281735311305374" STUDY_ID="STD-MRC-LU11" TOTAL_1="154" TOTAL_2="154" VAR="60.87" WEIGHT="15.423011629969341"/>
<IPD_DATA CI_END="1.4746258530925918" CI_START="0.7460698721618919" EFFECT_SIZE="1.0488917588118474" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="62" LOG_CI_END="0.168681843670585" LOG_CI_START="-0.1272204973619966" LOG_EFFECT_SIZE="0.02073067315429418" ORDER="7" O_E="1.58" SE="0.17381449986274955" STUDY_ID="STD-GETCB-04CB86" TOTAL_1="99" TOTAL_2="90" VAR="33.1" WEIGHT="8.386753490257684"/>
<IPD_DATA CI_END="1.584543039209077" CI_START="0.588261558646536" EFFECT_SIZE="0.9654666011766802" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="33" LOG_CI_END="0.1999040399524186" LOG_CI_START="-0.2304295306932222" LOG_EFFECT_SIZE="-0.015262745370401808" ORDER="8" O_E="-0.55" SE="0.2527800695827793" STUDY_ID="STD-Slovenia-1988" TOTAL_1="35" TOTAL_2="39" VAR="15.65" WEIGHT="3.9653381305901134"/>
<IPD_DATA CI_END="1.589103828232585" CI_START="1.0098582515730006" EFFECT_SIZE="1.266795016388571" ESTIMABLE="YES" EVENTS_1="161" EVENTS_2="141" LOG_CI_END="0.20115227389419063" LOG_CI_START="0.00426041845598296" LOG_EFFECT_SIZE="0.1027063461750868" ORDER="9" O_E="17.68" SE="0.11565525051480624" STUDY_ID="STD-GETCB-05CB88" TOTAL_1="274" TOTAL_2="265" VAR="74.76" WEIGHT="18.942407581017054"/>
<IPD_DATA CI_END="0.946946855729036" CI_START="0.33657248883834856" EFFECT_SIZE="0.5645496081217045" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="35" LOG_CI_END="-0.023674393659096345" LOG_CI_START="-0.47292138578737963" LOG_EFFECT_SIZE="-0.24829788972323805" MODIFIED="2015-03-10 12:37:28 +0000" MODIFIED_BY="[Empty name]" ORDER="10" O_E="-8.21" SE="0.2638899069846298" STUDY_ID="STD-Italy-2002" TOTAL_1="51" TOTAL_2="53" VAR="14.36" WEIGHT="3.6384827830846023"/>
<IPD_DATA CI_END="1.5063078758731532" CI_START="0.6638749063303778" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="44" LOG_CI_END="0.17791374684970776" LOG_CI_START="-0.1779137468497078" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-07-22 10:02:15 +0100" MODIFIED_BY="[Empty name]" ORDER="112" O_E="0.0" SE="0.20901483117353756" STUDY_ID="STD-Korea-2007" TOTAL_1="56" TOTAL_2="55" VAR="22.89" WEIGHT="5.799782096434996"/>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="16.654094958406084" CI_END="1.3066155026152382" CI_START="1.066528202570665" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_SIZE="1.1804839191853467" ESTIMABLE="YES" EVENTS_1="777" EVENTS_2="734" I2="39.95470768615654" I2_Q="40.85779853207464" ID="CMP-001.05" LOG_CI_END="0.11614780666284938" LOG_CI_START="0.02797234413506962" LOG_EFFECT_SIZE="0.07206007539895949" MODIFIED="2016-09-09 10:26:35 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.08237711229342348" P_Q="0.1843648336778857" P_Z="0.0013576691282737529" Q="3.3816800023662656" SCALE="5.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1163" TOTAL_2="1180" WEIGHT="100.0" Z="3.2035023907179396">
<NAME>RT delivery method</NAME>
<GROUP_LABEL_1>Surgery + PORT</GROUP_LABEL_1>
<GROUP_LABEL_2>Surgery</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="0.0" CI_END="2.017235848880563" CI_START="1.0909617226750858" DF="0" EFFECT_SIZE="1.483484781430763" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="80" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="0.30475667752827656" LOG_CI_START="0.037809513262387726" LOG_EFFECT_SIZE="0.17128309539533218" MODIFIED="2016-09-09 10:26:35 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.011897512982182485" STUDIES="1" TAU2="0.0" TOTAL_1="98" TOTAL_2="104" WEIGHT="10.910505419036378" Z="2.515169614620904">
<NAME>Cobalt-60 only</NAME>
<IPD_DATA CI_END="2.017235848880563" CI_START="1.0909617226750858" EFFECT_SIZE="1.483484781430763" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="80" LOG_CI_END="0.30475667752827656" LOG_CI_START="0.037809513262387726" LOG_EFFECT_SIZE="0.17128309539533218" MODIFIED="2014-07-07 14:24:54 +0100" MODIFIED_BY="[Empty name]" ORDER="60" O_E="16.04" SE="0.15680608569955762" STUDY_ID="STD-Belgium-1966" TOTAL_1="98" TOTAL_2="104" VAR="40.67" WEIGHT="10.910505419036378"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="8.19647284230177" CI_END="1.3280424868098348" CI_START="1.0460056551113532" DF="5" EFFECT_SIZE="1.1786178139801011" ESTIMABLE="YES" EVENTS_1="563" EVENTS_2="528" I2="38.998150836355634" ID="CMP-001.05.02" LOG_CI_END="0.1232119692277114" LOG_CI_START="0.019534032501634255" LOG_EFFECT_SIZE="0.07137300086467287" MODIFIED="2016-09-09 10:26:35 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.14573503473196625" P_Z="0.0069648479046772885" STUDIES="6" TAU2="0.0" TOTAL_1="871" TOTAL_2="875" WEIGHT="72.33072218049146" Z="2.698520352172866">
<NAME>Cobalt-60 and linac</NAME>
<IPD_DATA CI_END="1.3721870877704996" CI_START="0.7643548212494584" EFFECT_SIZE="1.0241278319592897" ESTIMABLE="YES" EVENTS_1="83" EVENTS_2="100" LOG_CI_END="0.13741332831468508" LOG_CI_START="-0.11670499071947658" LOG_EFFECT_SIZE="0.010354168797604247" MODIFIED="2014-07-07 14:25:47 +0100" MODIFIED_BY="[Empty name]" ORDER="65" O_E="1.07" SE="0.14927035850663303" STUDY_ID="STD-CAMS-1981" TOTAL_1="153" TOTAL_2="164" VAR="44.88" WEIGHT="12.039918446185213"/>
<IPD_DATA CI_END="1.6576688095456495" CI_START="0.8252887363842315" EFFECT_SIZE="1.169639002929315" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="59" LOG_CI_END="0.21949776592815637" LOG_CI_START="-0.08339408214081245" LOG_EFFECT_SIZE="0.06805184189367196" MODIFIED="2014-07-07 14:26:45 +0100" MODIFIED_BY="[Empty name]" ORDER="61" O_E="4.95" SE="0.17792017089454126" STUDY_ID="STD-GETCB-04CB86" TOTAL_1="99" TOTAL_2="90" VAR="31.59" WEIGHT="8.474621740530099"/>
<IPD_DATA CI_END="1.847682582328463" CI_START="1.144905871912594" EFFECT_SIZE="1.4544492558829551" ESTIMABLE="YES" EVENTS_1="152" EVENTS_2="120" LOG_CI_END="0.2666273648367123" LOG_CI_START="0.05876978275508019" LOG_EFFECT_SIZE="0.1626985737958962" MODIFIED="2014-07-07 14:27:55 +0100" MODIFIED_BY="[Empty name]" ORDER="62" O_E="25.13" SE="0.12209657262637609" STUDY_ID="STD-GETCB-05CB88" TOTAL_1="274" TOTAL_2="265" VAR="67.08" WEIGHT="17.995493078656505"/>
<IPD_DATA CI_END="1.5254738113665507" CI_START="0.8271778278213889" EFFECT_SIZE="1.1233156785537175" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="81" LOG_CI_END="0.18340475627431357" LOG_CI_START="-0.0824011151880868" LOG_EFFECT_SIZE="0.05050182054311342" MODIFIED="2014-07-07 14:25:31 +0100" MODIFIED_BY="[Empty name]" ORDER="63" O_E="4.77" SE="0.15613568465729805" STUDY_ID="STD-LCSG-773" TOTAL_1="110" TOTAL_2="120" VAR="41.02" WEIGHT="11.004399613692456"/>
<IPD_DATA CI_END="2.249111532816738" CI_START="1.037379460389167" EFFECT_SIZE="1.5274757308279827" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="45" LOG_CI_END="0.3520109925124774" LOG_CI_START="0.01593764492231189" LOG_EFFECT_SIZE="0.18397431871739464" MODIFIED="2014-07-07 14:26:03 +0100" MODIFIED_BY="[Empty name]" ORDER="64" O_E="10.87" SE="0.19741114796436382" STUDY_ID="STD-Lille-1985" TOTAL_1="81" TOTAL_2="82" VAR="25.66" WEIGHT="6.883785813928533"/>
<IPD_DATA CI_END="1.2368508587477591" CI_START="0.7437247571719126" EFFECT_SIZE="0.9591019781962963" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="123" LOG_CI_END="0.09231733493403664" LOG_CI_START="-0.12858776144085815" LOG_EFFECT_SIZE="-0.018135213253410727" MODIFIED="2014-07-07 14:26:29 +0100" MODIFIED_BY="[Empty name]" ORDER="66" O_E="-2.48" SE="0.12976074710847596" STUDY_ID="STD-MRC-LU11" TOTAL_1="154" TOTAL_2="154" VAR="59.39" WEIGHT="15.932503487498657"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="5.075942113738051" CI_END="1.3125726419580797" CI_START="0.7993423042388685" DF="3" EFFECT_SIZE="1.0243021234497518" ESTIMABLE="YES" EVENTS_1="126" EVENTS_2="126" I2="40.89767115585318" ID="CMP-001.05.03" LOG_CI_END="0.11812334798546038" LOG_CI_START="-0.0972672019039852" LOG_EFFECT_SIZE="0.010428073040737553" MODIFIED="2016-09-09 10:26:35 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.16632021159067267" P_Z="0.8494797948024926" STUDIES="4" TAU2="0.0" TOTAL_1="194" TOTAL_2="201" WEIGHT="16.758772400472154" Z="0.18978221280821664">
<NAME>Linac only</NAME>
<IPD_DATA CI_END="2.94291697221189" CI_START="0.9121952180847275" EFFECT_SIZE="1.6384488973636226" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="20" LOG_CI_END="0.46877800962972616" LOG_CI_START="-0.03991220875026487" LOG_EFFECT_SIZE="0.21443290043973065" MODIFIED="2014-07-07 14:26:15 +0100" MODIFIED_BY="[Empty name]" ORDER="67" O_E="5.53" SE="0.2988071523335984" STUDY_ID="STD-EORTC-08861" TOTAL_1="52" TOTAL_2="54" VAR="11.2" WEIGHT="3.004614228994527"/>
<IPD_DATA CI_END="1.2195710990480133" CI_START="0.41443698556984343" EFFECT_SIZE="0.710939779431113" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="30" LOG_CI_END="0.0862071240627354" LOG_CI_START="-0.38254149382234626" LOG_EFFECT_SIZE="-0.14816718487980543" MODIFIED="2014-07-07 14:28:16 +0100" MODIFIED_BY="[Empty name]" ORDER="69" O_E="-4.5" SE="0.2753452584887775" STUDY_ID="STD-Italy-2002" TOTAL_1="51" TOTAL_2="53" VAR="13.19" WEIGHT="3.538469792896233"/>
<IPD_DATA CI_END="1.73318274897865" CI_START="0.757786445721962" EFFECT_SIZE="1.1460289678429383" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="43" LOG_CI_END="0.23884435768713247" LOG_CI_START="-0.12045316707475373" LOG_EFFECT_SIZE="0.05919559530618934" MODIFIED="2016-04-04 10:40:22 +0100" MODIFIED_BY="[Empty name]" ORDER="66" O_E="3.06" SE="0.21105314459656363" STUDY_ID="STD-Korea-2007" TOTAL_1="56" TOTAL_2="55" VAR="22.45" WEIGHT="6.022641914368494"/>
<IPD_DATA CI_END="1.3910373132475855" CI_START="0.5160953803809419" EFFECT_SIZE="0.847294477324499" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="33" LOG_CI_END="0.14333877968304953" LOG_CI_START="-0.28727002832405046" LOG_EFFECT_SIZE="-0.07196562432050048" MODIFIED="2014-07-07 14:27:02 +0100" MODIFIED_BY="[Empty name]" ORDER="68" O_E="-2.59" SE="0.25294174537134734" STUDY_ID="STD-Slovenia-1988" TOTAL_1="35" TOTAL_2="39" VAR="15.63" WEIGHT="4.193046464212898"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="16.65409495840609" CI_END="1.3066155026152382" CI_START="1.0665282025706648" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_SIZE="1.1804839191853465" ESTIMABLE="YES" EVENTS_1="777" EVENTS_2="734" I2="39.95470768615656" I2_Q="80.4731082039748" ID="CMP-001.06" LOG_CI_END="0.11614780666284938" LOG_CI_START="0.027972344135069528" LOG_EFFECT_SIZE="0.07206007539895941" MODIFIED="2016-09-09 10:26:35 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.08237711229342282" P_Q="0.02363608459652855" P_Z="0.0013576691282737568" Q="5.121142732012041" SCALE="100.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1163" TOTAL_2="1180" WEIGHT="100.0" Z="3.2035023907179387">
<NAME>RT dose</NAME>
<GROUP_LABEL_1>Surgery + PORT</GROUP_LABEL_1>
<GROUP_LABEL_2>Surgery</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="0.19009995469960253" CI_END="1.1719921569266003" CI_START="0.7453741623258798" DF="1" EFFECT_SIZE="0.9346510965176609" ESTIMABLE="YES" EVENTS_1="146" EVENTS_2="156" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="0.06892470535536883" LOG_CI_START="-0.12762566571925812" LOG_EFFECT_SIZE="-0.029350480181944638" MODIFIED="2016-09-09 10:26:35 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.662833446785542" P_Z="0.5583089550324962" STUDIES="2" TAU2="0.0" TOTAL_1="189" TOTAL_2="193" WEIGHT="20.125549951711555" Z="0.5853551308099689">
<NAME>&lt; 45 Gy</NAME>
<IPD_DATA CI_END="1.2368508587477591" CI_START="0.7437247571719126" EFFECT_SIZE="0.9591019781962963" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="123" LOG_CI_END="0.09231733493403664" LOG_CI_START="-0.12858776144085815" LOG_EFFECT_SIZE="-0.018135213253410727" MODIFIED="2016-04-04 10:34:33 +0100" MODIFIED_BY="[Empty name]" ORDER="56" O_E="-2.48" SE="0.12976074710847596" STUDY_ID="STD-MRC-LU11" TOTAL_1="154" TOTAL_2="154" VAR="59.39" WEIGHT="15.932503487498657"/>
<IPD_DATA CI_END="1.3910373132475855" CI_START="0.5160953803809419" EFFECT_SIZE="0.847294477324499" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="33" LOG_CI_END="0.14333877968304953" LOG_CI_START="-0.28727002832405046" LOG_EFFECT_SIZE="-0.07196562432050048" MODIFIED="2016-04-04 10:34:53 +0100" MODIFIED_BY="[Empty name]" ORDER="57" O_E="-2.59" SE="0.25294174537134734" STUDY_ID="STD-Slovenia-1988" TOTAL_1="35" TOTAL_2="39" VAR="15.63" WEIGHT="4.193046464212898"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="11.342852271694452" CI_END="1.402627249877719" CI_START="1.1175878195424644" DF="8" EFFECT_SIZE="1.2520220165083693" ESTIMABLE="YES" EVENTS_1="631" EVENTS_2="578" I2="29.471002457083753" ID="CMP-001.06.02" LOG_CI_END="0.14694227200506135" LOG_CI_START="0.048281659807698794" LOG_EFFECT_SIZE="0.09761196590638006" MODIFIED="2016-09-09 10:26:35 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.18301921496027707" P_Z="1.0520462703628016E-4" STUDIES="9" TAU2="0.0" TOTAL_1="974" TOTAL_2="987" WEIGHT="79.87445004828844" Z="3.8782637442781054">
<NAME>&#8805; 45 Gy</NAME>
<IPD_DATA CI_END="2.017235848880563" CI_START="1.0909617226750858" EFFECT_SIZE="1.483484781430763" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="80" LOG_CI_END="0.30475667752827656" LOG_CI_START="0.037809513262387726" LOG_EFFECT_SIZE="0.17128309539533218" MODIFIED="2016-04-04 10:35:59 +0100" MODIFIED_BY="[Empty name]" ORDER="58" O_E="16.04" SE="0.15680608569955762" STUDY_ID="STD-Belgium-1966" TOTAL_1="98" TOTAL_2="104" VAR="40.67" WEIGHT="10.910505419036378"/>
<IPD_DATA CI_END="1.3721870877704996" CI_START="0.7643548212494584" EFFECT_SIZE="1.0241278319592897" ESTIMABLE="YES" EVENTS_1="83" EVENTS_2="100" LOG_CI_END="0.13741332831468508" LOG_CI_START="-0.11670499071947658" LOG_EFFECT_SIZE="0.010354168797604247" MODIFIED="2016-04-04 10:36:15 +0100" MODIFIED_BY="[Empty name]" ORDER="59" O_E="1.07" SE="0.14927035850663303" STUDY_ID="STD-CAMS-1981" TOTAL_1="153" TOTAL_2="164" VAR="44.88" WEIGHT="12.039918446185213"/>
<IPD_DATA CI_END="2.94291697221189" CI_START="0.9121952180847275" EFFECT_SIZE="1.6384488973636226" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="20" LOG_CI_END="0.46877800962972616" LOG_CI_START="-0.03991220875026487" LOG_EFFECT_SIZE="0.21443290043973065" MODIFIED="2016-04-04 10:36:28 +0100" MODIFIED_BY="[Empty name]" ORDER="60" O_E="5.53" SE="0.2988071523335984" STUDY_ID="STD-EORTC-08861" TOTAL_1="52" TOTAL_2="54" VAR="11.2" WEIGHT="3.004614228994527"/>
<IPD_DATA CI_END="1.6576688095456495" CI_START="0.8252887363842315" EFFECT_SIZE="1.169639002929315" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="59" LOG_CI_END="0.21949776592815637" LOG_CI_START="-0.08339408214081245" LOG_EFFECT_SIZE="0.06805184189367196" MODIFIED="2016-04-04 10:36:46 +0100" MODIFIED_BY="[Empty name]" ORDER="61" O_E="4.95" SE="0.17792017089454126" STUDY_ID="STD-GETCB-04CB86" TOTAL_1="99" TOTAL_2="90" VAR="31.59" WEIGHT="8.474621740530099"/>
<IPD_DATA CI_END="1.847682582328463" CI_START="1.144905871912594" EFFECT_SIZE="1.4544492558829551" ESTIMABLE="YES" EVENTS_1="152" EVENTS_2="120" LOG_CI_END="0.2666273648367123" LOG_CI_START="0.05876978275508019" LOG_EFFECT_SIZE="0.1626985737958962" MODIFIED="2016-04-04 10:37:07 +0100" MODIFIED_BY="[Empty name]" ORDER="62" O_E="25.13" SE="0.12209657262637609" STUDY_ID="STD-GETCB-05CB88" TOTAL_1="274" TOTAL_2="265" VAR="67.08" WEIGHT="17.995493078656505"/>
<IPD_DATA CI_END="1.2195710990480133" CI_START="0.41443698556984343" EFFECT_SIZE="0.710939779431113" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="30" LOG_CI_END="0.0862071240627354" LOG_CI_START="-0.38254149382234626" LOG_EFFECT_SIZE="-0.14816718487980543" MODIFIED="2016-04-04 10:37:24 +0100" MODIFIED_BY="[Empty name]" ORDER="63" O_E="-4.5" SE="0.2753452584887775" STUDY_ID="STD-Italy-2002" TOTAL_1="51" TOTAL_2="53" VAR="13.19" WEIGHT="3.538469792896233"/>
<IPD_DATA CI_END="1.73318274897865" CI_START="0.757786445721962" EFFECT_SIZE="1.1460289678429383" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="43" LOG_CI_END="0.23884435768713247" LOG_CI_START="-0.12045316707475373" LOG_EFFECT_SIZE="0.05919559530618934" MODIFIED="2016-04-04 10:37:37 +0100" MODIFIED_BY="[Empty name]" ORDER="64" O_E="3.06" SE="0.21105314459656363" STUDY_ID="STD-Korea-2007" TOTAL_1="56" TOTAL_2="55" VAR="22.45" WEIGHT="6.022641914368494"/>
<IPD_DATA CI_END="1.5254738113665507" CI_START="0.8271778278213889" EFFECT_SIZE="1.1233156785537175" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="81" LOG_CI_END="0.18340475627431357" LOG_CI_START="-0.0824011151880868" LOG_EFFECT_SIZE="0.05050182054311342" MODIFIED="2016-04-04 10:37:52 +0100" MODIFIED_BY="[Empty name]" ORDER="65" O_E="4.77" SE="0.15613568465729805" STUDY_ID="STD-LCSG-773" TOTAL_1="110" TOTAL_2="120" VAR="41.02" WEIGHT="11.004399613692456"/>
<IPD_DATA CI_END="2.249111532816738" CI_START="1.037379460389167" EFFECT_SIZE="1.5274757308279827" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="45" LOG_CI_END="0.3520109925124774" LOG_CI_START="0.01593764492231189" LOG_EFFECT_SIZE="0.18397431871739464" MODIFIED="2016-04-04 10:38:06 +0100" MODIFIED_BY="[Empty name]" ORDER="66" O_E="10.87" SE="0.19741114796436382" STUDY_ID="STD-Lille-1985" TOTAL_1="81" TOTAL_2="82" VAR="25.66" WEIGHT="6.883785813928533"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2016-09-07 11:34:34 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2016-09-07 11:34:34 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiMAAADnCAMAAAD7EqYIAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD/gADAwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID///8AAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///9BjlLGAAAJx0lEQVR42u2dCXIbIRBFScoX4EocnCtxgZSTSJqFpdlm0TDy+3HK
1gxLG3+aZsRXKwVAGb+UZhBACe43YwAqgCMAjgA4AuAIgCMAjgA4Aj4dXwyBAMcQeM9W4QjuVcQ3
gwGYMACOADgC4AiAI+BDOWKeEMuZqww0ub5N/bXJVzOj/H43QPh8xD6Hyw5mo2hPi5W2/ZYd7rce
fq15uROjXl5l8i3+xcXdmLnIXHKavybTivFqioWmV9OPRkmlxL4DKwoVTWieyrlOIPoRf5JO/6ev
6KKy00ReS3kls60sBZWSWrXRq///bdDNfF2lBUNj8hWTJqZvOJJGjpjJDdvYI1sTummb9dvW5P16
6uBzzt9mFgrbuJwUyknWQI+ueGSaY82xgnmNsGkNdE35gukII9O++xYNE7QCmtcau3jn5oDSNM/6
uiew4UrV2XfX33ruwA4Ypt/j+Yhp2xom8z7aW5rSvtNU+jItfkCsY5pqLcE16ItZ7TOA82OF6ZXo
lKeL67epZFrhcdG/lis0v5pteM7xpO/JyqTJ2YpsxflubACuJIvjdXo9g73jD3P03zRoD2ma+l54
4a47Y2T27ScO3qviRt7pRz4BnFX0zio6zioWxwco3vcFcATAEQBHwPUgZmVfU4vb4QjuVQQaLMCE
AXAEwBEARwAcAXDkdXorq48q3GlvvXIPDdbgHDG2fiL5XMMP12DBhRyOeIa2HE+38wvzIJGd75jl
eKBfZrnsX1PL0cLX3bS88dgR1/EtyZrwanO9pTgXfz5HYplVWTmVCK2Ca6ueypN6BeUtGqx7rDXT
gWPBgVc1FJLyyebu2urSgQZrWD9iNoWbDS2ajjbRYA3Nkaw+qkO9JU10ubotWIEGa8y1ZlGuiBPT
dHsgU69ekYWiwRo7Zg2UTzXlVCiaSq6F4q9oTQkZigbrXbitdgIN1rnwNFi3HYyDH3rhRj7Qj5wK
ziqiwWoeH6B43xfAEQBHABwB14OYlX1NLW6HI7hXEWiwABMGwBEARwAcAXAEfChH5ixYRvh07o7s
WNvSwZTOsxb6zZ9lRYN1FILnI8vprcYcIOKhi30nMQ49xkEerDPXGpOkrwou+LM3yl+1prCaUlGt
WbPKabEK+anErFwqzM/l9UserBP9SOIQwtRW8QVjVVZWJWTNKqfFymmjVCYrl4oyadkwGxcarJP8
yCMeKYiVxHxWJZmUVb6UqthMSRtVqGhbVxk0WIfHI1tDzu4y+Ws2kPH2RrDtNqPB2rHWHB1rivoq
my8XrjVNfaPBuur5SDEFXtckNoVtaFEbVcuUhQbrXX7EiJvCSKawXniGeRlZlTCl0+RaSd4rv1yS
MUvoPyj4iFPRYJ2AbdqJeIvwAUCDFWJXHizP2XzQfhE3crQf+XRwVhENVvP4AMX7vgCOADgC4Ai4
HsSs7GtqcTscwb2KQIMFmDAAjgA4AuAIgCPgh3PE9Bc0Z7ZmvB+M/xMaLPzI9OcVjn6EB+pVroD3
GpIczRFJSOXJrTzJUyKQ8sovSqlMM0GVbGv+daPCf2iwDsDX9smbCKlWuVUsdLKipmqawPlmgiqm
0lp0HQ3W5WtNTslkVc3LV32/leuHl2vSr3z7aLDe5Uc2BLhmT+VKazs+qgAN1uUcsXsmqxXCUxP9
lL7qiHXRYL1jX9PwwSTFzwipOQKT3bRu9CRosN7rRyQBlndDCQIpleS8et6yGblUopfyqqxKMC/7
lpf9Fw3WMThHO/HWAT+mMzRYIT4hD1bobe7FavzIB4CzimiwmscHKN73BXAEwBEAR8D1IGZlX1OL
2+EI7lUEGizAhAFwBMARAEcAHAFwpAATaBEas1OV2utKwlWthwarG4c/HzHV5BX9JzXak3A190Qe
rBHWmlhy5WWnmpP2mWVSmzTZlZdXq5CEa0M9NFhX+5F5liYiKT87lfKuTz9mM2kFRcQkXF310GBd
70esyc/LVZsXrRRZOVRZOrWpHhqs6/3IHI/UdREHyKh2RZtosK6MWTNTuRg32h2c3GwpGqyrn49k
s1Mti3/qSswGv9FVDw3W5X7ETlNTlFwFW1Y5d1aqx/IneZSEa0M9NFjdGE070fCnWjcsm+q13EWD
tS8P1rUUUtuScJla4IIbuY8fGQOcVUSD1Tw+QPG+L4AjAI4AOAKuBzEr+5pa3A5HcK8i0GABJgyA
IwCOADgC4AiAI4NjVkVkTplldFhAxkc+HzF2r0QLfLgfmT8ofk6EtXqWRYiFDuun+5HZT4jarIlF
kg4L/MyYVRRooMPCj2TD1Mx1dFhwJMsAdFg/dK2Z0x3lXQk6rB/vR5alw8sQG8Yesg4LiEA7IQEN
1oflwQKsNZfMIoYAjpTB+vvp+xoARwAcAXAEwBEARwAcAQCOADiyF+7i+mM1AEcAfgTAEXA2OD9y
ymr+AeCzN1sHaCPH9k68ARpgrQHEIwCOAGJWME4AT8yaDdn085tuj/+WOs/vXVXXOFFv63uNM3Wz
Ba9bq9W5TuFIdvj+/39+NVNkHl09vWqvGmyntvS9Vneq1QIX/abZTolHjt4vb991On0YuQ/tDT9y
+F/ObaaLix/M9Petmy3Qzb8wHCm6Bvf4cs1x/bzU/P/eW1UtNTf2nbSzyQKpDhypr/C6az7rzVX1
7r73WiDXIR45cKlxO1eK/cuc3h/hpHXgyNF02v5+4FHvJB79jiTP0Mrho5ufM3Q9neitmjxg2dqA
7jFeej4i1HFwBNSIx1oDaoAjAI4AOALgCIAjYHR8Rft7ACZogSM8KQFKchmsNYB4BMARAEcAHAE3
2vsWdsGj7ngw9DKOxN7l+y7m/xnW0F/hy7+sNYB4BMCRpiU1czcp59x69R3P+53YkxvP+MXQXP+D
DOpR2omaqnToUO1q4/XYg9q/1jg3MX9hsnv+m+74M+RV0kXMn4qtpc9zKHNPvunzNzeO8a+GVWDs
QIPa7UckQanT4R3/9awwXoQ9oQj5XJLo9SvteTVsAOMfjQY9DTSoG9ca7aZ/kbPTiSNMHKJ+n5PU
Ykc6/H6h8S4a09SaIQb1QC2n9j5/oz4y2r0/OinEeJcY36DZGmFQv46dtg+2VxSmzvsQlTeTRAcG
3MP4Aez6vdlpaBV9mEnr5tiLds8ZVZe4ZlfZGA9hvNvzxOHMQf3q/B103p2td17kCUtqt9x83Tlv
rYma9nt+/DQZMJbxolGDDKqn5XTZzNDfw75VFr9fM6yh8fs1uvbQ43qTdWaQwVV/ETXue8FwZAyM
fFZA5shtUqn/uYuhf2/M36+7kRpD3w7OBgA4AuAIgCMAjgA4Au4Of+/Lh0uACkf4aAnAWgPgCIAj
AI4AOALgCIAjAAAg4B9fJnADKSz9zAAAAABJRU5ErkJggg==
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2016-09-07 11:34:34 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAASYAAAJkCAIAAAAz3ht3AAAW10lEQVR42u3dva7kxhGG4b2ADRTo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</FILE>
</FIGURE>
<FIGURE FILENAME="SurvSC.jpg" FILE_TYPE="JPG" ID="FIG-03" MODIFIED="2016-09-07 11:34:33 +0100" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Overall survival.</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
<FIGURE FILENAME="figure 2.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2016-09-07 11:34:33 +0100" MODIFIED_BY="[Empty name]" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>PORT effect on overall survival by trial according to stage.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlkAAAKtCAMAAAAjJYt6AAADAFBMVEUAAAAAADoAOjo6AAA6OjoA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=
</FILE>
</FIGURE>
<FIGURE FILENAME="figure 3.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2016-09-07 11:34:33 +0100" MODIFIED_BY="[Empty name]" NO="5" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Hazard ratio (HR) for the interaction between the effect of PORT on survival and (a) stage or (b) nodal status.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAtAAAAPACAMAAAArKL6BAAADAFBMVEUAAAAAADoTEy4AAGYAAGQA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</FILE>
</FIGURE>
<FIGURE FILENAME="fig3.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2016-09-07 11:34:33 +0100" MODIFIED_BY="[Empty name]" NO="6" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Sensitivity analysis 1: only trials with all stage subgroups included.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA7EAAAK0CAYAAADVmbpeAABDI0lEQVR42u3dT2gmZ54f8DZZNA7K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</FILE>
</FIGURE>
<FIGURE FILENAME="fig4.png" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2016-09-07 11:34:33 +0100" MODIFIED_BY="[Empty name]" NO="7" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Sensitivity analysis (2): only trials with stage II and III subgroups represented.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA8AAAALQCAMAAABoqemGAAADAFBMVEUAAAAGBgYRERELCwseHh4d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</FILE>
</FIGURE>
<FIGURE FILENAME="figure 4.png" FILE_TYPE="PNG" ID="FIG-08" MODIFIED="2016-09-07 11:34:33 +0100" MODIFIED_BY="[Empty name]" NO="8" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>PORT effect on overall survival by trial according to nodal status.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAKrCAMAAAAavgNZAAADAFBMVEUAAAAAADoAOjo6AAA6ADo6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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2016-09-07 11:36:03 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2016-09-07 11:36:03 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2016-09-07 11:36:03 +0100" MODIFIED_BY="[Empty name]">MEDLINE search strategy (via PubMed)</TITLE>
<APPENDIX_BODY MODIFIED="2016-07-20 09:32:39 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="2" ROWS="39">
<TR>
<TD VALIGN="TOP">
<P>#1</P>
</TD>
<TD VALIGN="TOP">
<P>Search Carcinoma, Non-Small-Cell Lung[MeSH Terms]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#2</P>
</TD>
<TD VALIGN="TOP">
<P>Search nsclc[Title/Abstract]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#3</P>
</TD>
<TD VALIGN="TOP">
<P>Search lung cancer*[Title/Abstract]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#4</P>
</TD>
<TD VALIGN="TOP">
<P>Search lung carcinoma[Title/Abstract]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#5</P>
</TD>
<TD VALIGN="TOP">
<P>Search lung neoplasm*[Title/Abstract]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#6</P>
</TD>
<TD VALIGN="TOP">
<P>Search lung tumor*[Title/Abstract]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#7</P>
</TD>
<TD VALIGN="TOP">
<P>Search lung tumour*[Title/Abstract]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#8</P>
</TD>
<TD VALIGN="TOP">
<P>Search non-small cell*[Title/Abstract]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#9</P>
</TD>
<TD VALIGN="TOP">
<P>Search nonsmall cell*[Title/Abstract]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#10</P>
</TD>
<TD VALIGN="TOP">
<P>Search (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7) AND (#8 OR #9)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#11</P>
</TD>
<TD VALIGN="TOP">
<P>Search Thoracic surgery[MeSH Terms]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#12</P>
</TD>
<TD VALIGN="TOP">
<P>Search surg*[Title/Abstract]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#13</P>
</TD>
<TD VALIGN="TOP">
<P>Search thoracic surgical procedures[MeSH Terms]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#14</P>
</TD>
<TD VALIGN="TOP">
<P>Search pneumonectomy[MeSH Terms]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#15</P>
</TD>
<TD VALIGN="TOP">
<P>Search pneumonectom*[Title/Abstract]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#16</P>
</TD>
<TD VALIGN="TOP">
<P>Search lobectom*[Title/Abstract]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#17</P>
</TD>
<TD VALIGN="TOP">
<P>Search Lung/surgery[MeSH Terms]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#18</P>
</TD>
<TD VALIGN="TOP">
<P>Search thoracotomy[MeSH Terms]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#19</P>
</TD>
<TD VALIGN="TOP">
<P>Search Thoracotom*[Title/Abstract]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#20</P>
</TD>
<TD VALIGN="TOP">
<P>Search Radiotherapy[MeSH Terms]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#21</P>
</TD>
<TD VALIGN="TOP">
<P>Search Radiother*[Title/Abstract]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#22</P>
</TD>
<TD VALIGN="TOP">
<P>Search PORT[Title/Abstract]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#23</P>
</TD>
<TD VALIGN="TOP">
<P>Search radiation therap*[Title/Abstract]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#24</P>
</TD>
<TD VALIGN="TOP">
<P>Search (#11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19) AND (#20 OR #21 OR #22 OR #23)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#25</P>
</TD>
<TD VALIGN="TOP">
<P>Search #10 AND #24</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#26</P>
</TD>
<TD VALIGN="TOP">
<P>Search randomized controlled trial[Publication Type]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#27</P>
</TD>
<TD VALIGN="TOP">
<P>Search controlled clinical trial[Publication Type]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#28</P>
</TD>
<TD VALIGN="TOP">
<P>Search randomized[Title/Abstract]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#29</P>
</TD>
<TD VALIGN="TOP">
<P>Search placebo[Title/Abstract]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#30</P>
</TD>
<TD VALIGN="TOP">
<P>Search drug therapy[MeSH Terms]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#31</P>
</TD>
<TD VALIGN="TOP">
<P>Search randomly[Title/Abstract]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#32</P>
</TD>
<TD VALIGN="TOP">
<P>Search trial[Title/Abstract]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#33</P>
</TD>
<TD VALIGN="TOP">
<P>Search groups[Title/Abstract]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#34</P>
</TD>
<TD VALIGN="TOP">
<P>Search (#25 OR #26 OR #27 OR #28 OR #29 OR #30OR #31 OR #32 OR #33)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#35</P>
</TD>
<TD VALIGN="TOP">
<P>Search animals[MeSH Terms]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#36</P>
</TD>
<TD VALIGN="TOP">
<P>Search humans[MeSH Terms]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#37</P>
</TD>
<TD VALIGN="TOP">
<P>Search #35 NOT #36</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#38</P>
</TD>
<TD VALIGN="TOP">
<P>Search #34 NOT #37</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#39</P>
</TD>
<TD VALIGN="TOP">
<P>Search #25 AND #38</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2016-07-20 09:37:30 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2016-07-20 09:22:29 +0100" MODIFIED_BY="[Empty name]">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-07-20 09:37:30 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="2" ROWS="22">
<TR>
<TD VALIGN="TOP">
<P>#1</P>
</TD>
<TD VALIGN="TOP">
<P>lung cancer*</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#2</P>
</TD>
<TD VALIGN="TOP">
<P>non-small cell*</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#3</P>
</TD>
<TD VALIGN="TOP">
<P>non small cell*</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#4</P>
</TD>
<TD VALIGN="TOP">
<P>nonsmall cell*</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#5</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Lung Neoplasms] explode all trees</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#6</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Carcinoma, Non-Small-Cell Lung] explode all trees</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#7</P>
</TD>
<TD VALIGN="TOP">
<P>Nsclc</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#8</P>
</TD>
<TD VALIGN="TOP">
<P>#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#9</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Thoracic Surgery] explode all trees</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#10</P>
</TD>
<TD VALIGN="TOP">
<P>surg*</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#11</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Thoracic Surgical Procedures] explode all trees</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#12</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Pneumonectomy] explode all trees</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#13</P>
</TD>
<TD VALIGN="TOP">
<P>pneumonectom*</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#14</P>
</TD>
<TD VALIGN="TOP">
<P>lobectom*</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#15</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Lung] explode all trees and with qualifier(s): [Surgery - SU]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#16</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Thoracotomy] explode all trees</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#17</P>
</TD>
<TD VALIGN="TOP">
<P>thoracotom*</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#18</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Radiotherapy] explode all trees</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#19</P>
</TD>
<TD VALIGN="TOP">
<P>Radiotherap*</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#20</P>
</TD>
<TD VALIGN="TOP">
<P>radiation therap*</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#21</P>
</TD>
<TD VALIGN="TOP">
<P>PORT</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#22</P>
</TD>
<TD VALIGN="TOP">
<P>(#9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17) and (#18 or #19 or #20 or #21)</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>